

# CITATION REPORT

List of articles citing

Bladder cancer: epidemiology, staging and grading, and diagnosis

DOI: 10.1016/j.urology.2005.07.062  
Urology, 2005, 66, 4-34.

**Source:** <https://exaly.com/paper-pdf/39390982/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
752	Low-grade Ta (noninvasive) urothelial carcinoma of the bladder. <i>Urology</i> , <b>2005</b> , 66, 75-89	1.6	32
751	Hexyl aminolevulinate in the detection of bladder cancer: profile report. <b>2006</b> , 20, 317-20		
750	Use of selenium in chemoprevention of bladder cancer. <b>2006</b> , 7, 766-74		40
749	Hexyl aminolevulinate: in the detection of bladder cancer. <b>2006</b> , 66, 571-8; discussion 579-80		18
748	Polymorphisms in the E-cadherin (CDH1) gene promoter and the risk of bladder cancer. <b>2006</b> , 42, 3219-27		21
747	The diagnosis and staging of bladder cancer: from RBCs to TURs. <i>Urology</i> , <b>2006</b> , 67, 3-8; discussion 8-10	1.6	37
746	The role of the surgeon and transurethral resection in the treatment of superficial bladder cancer. <b>2006</b> , 6, 2626-31		6
745	Bibliography. Current world literature. Bladder cancer. <i>Current Opinion in Urology</i> , <b>2006</b> , 16, 386-9	2.8	
744	Intravesical gemcitabine: an update of clinical results. <i>Current Opinion in Urology</i> , <b>2006</b> , 16, 361-6	2.8	14
743	The pathology of bladder cancer: An update on selected issues. <b>2006</b> , 98, 1161-5		13
742	Fluorescence diagnosis of bladder cancer. <b>2006</b> , 15, 595-7		10
741	Recent improvements in the detection and treatment of nonmuscle-invasive bladder cancer. <b>2006</b> , 6, 1301-11		8
740	The E-cadherin gene polymorphism 160C->A and cancer risk: A HuGE review and meta-analysis of 26 case-control studies. <b>2008</b> , 167, 7-14		57
739	The role of hexaminolevulinate fluorescence cystoscopy in bladder cancer. <b>2007</b> , 4, 542-9		80
738	Anatomical location of urothelial carcinomas of the urinary tract leads to perspectives of specific treatment. <b>2007</b> , 3, 595-9		7
737	Pooled analysis and meta-analysis of the glutathione S-transferase P1 Ile 105Val polymorphism and bladder cancer: a HuGE-GSEC review. <b>2007</b> , 165, 1221-30		68
736	Atlas of Urogynecological Endoscopy. <b>2007</b> ,		2

735	Prognostic effect of DNA aneuploidy from bladder washings in superficial bladder cancer. <b>2007</b> , 16, 979-83		7
734	Current strategies for first and second line intravesical therapy for nonmuscle invasive bladder cancer. <i>Current Opinion in Urology</i> , <b>2007</b> , 17, 352-7	2.8	22
733	Bladder Cancer: Management and Future Directions. <b>2007</b> , 6, 365-373		9
732	Treatment of Intermediate-Risk NonMuscle-Invasive Bladder Cancer (NMIBC). <b>2007</b> , 6, 800-808		6
731	Introduction. <i>Urology</i> , <b>2007</b> , 69, 1-2	1.6	5
730	Searching urinary tumor markers for bladder cancer using a two-dimensional differential gel electrophoresis (2D-DIGE) approach. <b>2007</b> , 6, 4440-8		70
729	[The 2004 WHO classification of bladder tumors: a summary and commentary]. <b>2007</b> , 31, 978-88		6
728	Imaging of bladder cancer. <b>2007</b> , 45, 183-205		68
727	Lack of BK virus DNA sequences in most transitional-cell carcinomas of the bladder. <b>2007</b> , 120, 1248-51		35
726	Three-dimensional ultrasonography of the urinary bladder: preliminary experience of assessment in patients with haematuria. <b>2007</b> , 99, 111-6		37
725	A validated mouse model for orthotopic bladder cancer using transurethral tumour inoculation and bioluminescence imaging. <b>2007</b> , 100, 1377-84		57
724	On the origin of syn- and metachronous urothelial carcinomas. <b>2007</b> , 51, 1185-93; discussion 1193		35
723	Re: Nephroureterectomy for treating upper urinary tract transitional cell carcinoma. time to change the treatment paradigm?. <b>2007</b> , 51, 1141-2		1
722	Re: Poorly differentiated prostate cancer treated with radical prostatectomy: long-term outcome and incidence of pathological downgrading. <b>2007</b> , 51, 1142-3		2
721	Advances in the management of superficial bladder cancer. <b>2007</b> , 34, 85-97		33
720	Increased CYP1A1 expression in human exfoliated urothelial cells of cigarette smokers compared to non-smokers. <b>2007</b> , 81, 19-25		19
719	[Fluorescence cystoscopy at bladder cancer: present trials]. <b>2007</b> , 46, 1519-27		5
718	[Cytology of the urinary tract. A modern investigation method?]. <b>2007</b> , 28, 354-9		2

717	Urinary tract diseases and bladder cancer risk: a case-control study. <b>2007</b> , 18, 839-45		20
716	Stellenwert der transurethralen Resektion und Instillationstherapie beim Harnblasenkarzinom. <b>2007</b> , 13, 1080-1088		
715	Blindness in a bladder cancer patient. <b>2007</b> , 9, 117-8		3
714	[Diagnosis of urothelial carcinoma]. <b>2008</b> , 47, 357-67		1
713	[Transitional cell carcinoma of the bladder. Evaluation of plasma levels of cellular fibronectin as a stage-dependent marker]. <b>2008</b> , 47, 1137-40		0
712	Evaluation of an orthotopic rat bladder urothelial cell carcinoma model by cystoscopy. <b>2008</b> , 101, 889-93		19
711	Paclitaxel and cisplatin as intravesical agents against non-muscle-invasive bladder cancer. <b>2008</b> , 101, 1347-55		36
710	A comparison of the performance of microsatellite and methylation urine analysis for predicting the recurrence of urothelial cell carcinoma, and definition of a set of markers by Bayesian network analysis. <b>2008</b> , 101, 1448-53		44
709	Predicting survival after radical cystectomy for bladder cancer. <b>2008</b> , 102, 15-22		38
708	Intravesically administered antisense oligonucleotides targeting heat-shock protein-27 inhibit the growth of non-muscle-invasive bladder cancer. <b>2008</b> , 102, 610-6		42
707	DNA methylation patterns in bladder cancer and washing cell sediments: a perspective for tumor recurrence detection. <b>2008</b> , 8, 238		34
706	Polymorphisms in the H19 gene and the risk of bladder cancer. <b>2008</b> , 54, 1118-26		105
705	Bladder cancer: clinical and pathological profile. <b>2008</b> , 95-109		64
704	Urinary cytology and quantitative BTA and UBC tests in surveillance of patients with pT <sub>ap</sub> T <sub>1</sub> bladder urothelial carcinoma. <i>Urology</i> , <b>2008</b> , 71, 718-22	1.6	47
703	Relationship between patient age and superficial transitional cell carcinoma characteristics. <i>Urology</i> , <b>2008</b> , 71, 1186-90	1.6	28
702	Hydronephrosis is an independent predictor of poor clinical outcome in patients treated for muscle-invasive transitional cell carcinoma with radical cystectomy. <i>Urology</i> , <b>2008</b> , 72, 379-83	1.6	26
701	Bladder Cancer: A Major Public Health Issue. <b>2008</b> , 7, 510-515		32
700	Routine Use of Photodynamic Diagnosis of Bladder Cancer: Practical and Economic Issues. <b>2008</b> , 7, 536-541		12

699	Diagnosis of Non-Muscle Invasive Bladder Cancer. <b>2008</b> , 7, 627-636	1
698	Current Approaches to the Management of Non-Muscle Invasive Bladder Cancer: Comparison of Current Guidelines and Recommendations. <b>2008</b> , 7, 637-650	18
697	Epidemiology, Staging, Grading, and Risk Stratification of Bladder Cancer. <b>2008</b> , 7, 618-626	69
696	Safety and side effects of immediate instillation of apaziquone following transurethral resection in patients with nonmuscle invasive bladder cancer. <b>2008</b> , 180, 116-20	16
695	Tissue microarray studies in bladder cancer. <b>2008</b> , 141-6	2
694	Identification of PMF1 methylation in association with bladder cancer progression. <b>2008</b> , 14, 8236-43	34
693	Clinical value of PTEN in patients with superficial bladder cancer. <b>2008</b> , 80, 264-9	12
692	Imaging of bladder cancer. <b>2008</b> , 20, 97-111	
691	A meta-analysis on XRCC1 R399Q and R194W polymorphisms, smoking and bladder cancer risk. <b>2008</b> , 23, 523-32	26
690	DNA repair polymorphisms modify bladder cancer risk: a multi-factor analytic strategy. <b>2008</b> , 65, 105-18	93
689	Nutrition, total fluid and bladder cancer. <b>2008</b> , 25-36	25
688	Development of a multiplex RNA urine test for the detection and stratification of transitional cell carcinoma of the bladder. <b>2008</b> , 14, 742-9	61
687	IMP3 predicts aggressive superficial urothelial carcinoma of the bladder. <b>2008</b> , 14, 1701-6	90
686	Apaziquone for non-muscle invasive bladder cancer: a critical review. <b>2008</b> , 17, 1085-96	12
685	Virtual cystoscopy. <b>2008</b> , 8, 449-54	3
684	Promoter hypermethylation in tumour suppressor genes shows association with stage, grade and invasiveness of bladder cancer. <b>2008</b> , 75, 145-51	56
683	Contemporary diagnosis of bladder cancer. <b>2008</b> , 2, 713-20	1
682	Imaging of metastatic bladder cancer. 79-92	

681	Imaging in the diagnosis of bladder cancer. 31-50		
680	Polyunsaturated fatty acid metabolizing 15-Lipoxygenase-1 (15-LO-1) expression in normal and tumorigenic human bladder tissues. <b>2008</b> , 16, 159-64		12
679	Detection of early bladder carcinoma by fluorescence cystoscopy with Hexvix(R): improvement of the specificity by microcystoscopy. <b>2008</b> ,		1
678	Urothelial Dysplasia and Its Mimics. <b>2008</b> , 13, 149-153		2
677	Phase III prevention trial of fenretinide in patients with resected non-muscle-invasive bladder cancer. <b>2008</b> , 14, 224-9		54
676	Follow-up of nonmuscle invasive transitional cell carcinoma of the bladder: how and how often?. <i>Current Opinion in Urology</i> , <b>2008</b> , 18, 504-7	2.8	6
675	Presentation and outcome following radical cystectomy in Hispanics with bladder cancer. <b>2008</b> , 34, 691-8; discussion 698		6
674	A Clinicopathological Study of Urinary Bladder Neoplasms in Patients at Three Centers in Khartoum, Sudan. <b>2009</b> , 4,		3
673	Outcome and quality of life in patients operated on with radical cystectomy and three different urinary diversion techniques. <b>2009</b> , 43, 37-41		19
672	Anti-inflammatory, anti-proliferative and antioxidant profiles of selective cyclooxygenase-2 inhibition as chemoprevention for rat bladder carcinogenesis. <b>2009</b> , 8, 1615-22		17
671	Strategies to improve drug delivery in bladder cancer therapy. <b>2009</b> , 6, 727-44		14
670	MDCT Urography: Exploring a new paradigm for imaging of bladder cancer. <b>2009</b> , 192, 1501-8		33
669	Emerging apoptosis agonists for bladder cancer. <b>2009</b> , 14, 607-18		4
668	EGFR pathway polymorphisms and bladder cancer susceptibility and prognosis. <b>2009</b> , 30, 1155-60		36
667	[Photodynamic diagnosis (PDD) in non-muscle invasive bladder cancer. Literature review]. <b>2009</b> , 33, 965-75		6
666	Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. <b>2009</b> , 56, 430-42		466
665	Clinical outcome in a contemporary series of restaged patients with clinical T1 bladder cancer. <b>2009</b> , 56, 903-10		86
664	Predictive value of telomerase reverse transcriptase expression in patients with high risk superficial bladder cancer treated with adjuvant BCG immunotherapy. <b>2009</b> , 135, 1169-75		12

663	Bladder cancer SNP panel predicts susceptibility and survival. <b>2009</b> , 125, 527-39	72
662	The role of neutrophils and TNF-related apoptosis-inducing ligand (TRAIL) in bacillus Calmette-Guérin (BCG) immunotherapy for urothelial carcinoma of the bladder. <b>2009</b> , 28, 345-53	43
661	Oncological risk of laparoscopic surgery in urothelial carcinomas. <b>2009</b> , 27, 81-8	42
660	Alterations to the protein profile of bladder carcinoma cell lines induced by plant extract MINA-05 in vitro. <b>2009</b> , 9, 1883-92	5
659	Staging and reporting of urothelial carcinoma of the urinary bladder. <b>2009</b> , 22 Suppl 2, S70-95	126
658	Non-muscle-invasive bladder cancer surveillance for which cystoscopy is partly replaced by microsatellite analysis of urine: a cost-effective alternative?. <b>2009</b> , 104, 41-7	29
657	Interest of methylated genes as biomarkers in urothelial cell carcinomas of the urinary tract. <b>2009</b> , 104, 896-901	43
656	Environmental factors involved in carcinogenesis of urothelial cell carcinomas of the upper urinary tract. <b>2009</b> , 104, 1436-40	178
655	Pathological stage review is indicated in primary pT1 bladder cancer. <b>2010</b> , 106, 206-11	42
654	Intravesical therapy for urothelial carcinoma of the urinary bladder: a critical review. <b>2009</b> , 35, 640-50; discussion 651	15
653	Characterization of Texture Features Between Carcinomatous and Normal Wall Tissue in MR Bladder Imaging. <b>2009</b> ,	
652	Cytology and Urinary Markers for the Diagnosis of Bladder Cancer. <b>2009</b> , 8, 536-541	31
651	Tratamiento de tumores vesicales por resección endoscópica. <b>2009</b> , 41, 1-7	
650	Cáncer de vejiga. <b>2009</b> , 10, 1787-1797	
649	[Primary upper urinary tract tumors and subsequent location in the bladder]. <b>2009</b> , 19, 583-8	7
648	HAL fluorescence cystoscopy: towards a new paradigm in bladder cancer management. <b>2009</b> ,	
647	Detection of early bladder carcinoma by fluorescence cystoscopy with Hexvix: optical characterization of a high magnification cystoscope. <b>2009</b> ,	
646	Bladder cancer detection by fluorescence imaging with Hexvix: optimization of the excitation light during high magnification cystoscopy. <b>2009</b> ,	

645	Unusual location of a urinary bladder cancer metastasis. <b>2009</b> , 4, 316	
644	Bladder cancer detection by fluorescence imaging with Hexvix: analysis and processing of images obtained during high magnification cystoscopy. <b>2009</b> ,	
643	Critical evaluation of vinflunine in the treatment of refractory metastatic urothelial carcinoma. <b>2010</b> , 99	
642	Screening adults for bladder cancer: a review of the evidence for the U.S. preventive services task force. <b>2010</b> , 153, 461-8	54
641	Microemulsions for intravesical delivery of gemcitabine. <b>2010</b> , 58, 1461-5	10
640	Imaging and photodynamic therapy: mechanisms, monitoring, and optimization. <b>2010</b> , 110, 2795-838	1670
639	In vivo bladder cancer diagnosis by high-volume Raman spectroscopy. <b>2010</b> , 82, 5993-9	143
638	Diagnosis of bladder cancer: contrast-enhanced ultrasound. <b>2010</b> , 35, 494-503	27
637	Treatment and outcome in muscle invasive bladder cancer: a population-based survey. <b>2010</b> , 28, 439-44	12
636	Promoter hypermethylation in tumour suppressor genes and response to interleukin-2 treatment in bladder cancer: a pilot study. <b>2010</b> , 136, 847-54	21
635	CK20 and Ki-67 as significant prognostic factors in human bladder carcinoma. <b>2010</b> , 10, 153-8	14
634	Intravesical gemcitabine for treatment of superficial bladder cancer not responding to Bacillus Calmette-Guérin vaccine. <b>2010</b> , 16, 110-116	
633	Minerals and vitamins and the risk of bladder cancer: results from the New Hampshire Study. <b>2010</b> , 21, 609-19	45
632	Intravesical drug delivery: Challenges, current status, opportunities and novel strategies. <b>2010</b> , 148, 147-59	172
631	An updated critical analysis of the treatment strategy for newly diagnosed high-grade T1 (previously T1G3) bladder cancer. <b>2010</b> , 57, 60-70	141
630	Molecular grade (FGFR3/MIB-1) and EORTC risk scores are predictive in primary non-muscle-invasive bladder cancer. <b>2010</b> , 58, 433-41	131
629	The suppressive effect of Rho kinase inhibitor, Y-27632, on oncogenic Ras/RhoA induced invasion/migration of human bladder cancer TSGH cells. <b>2010</b> , 183, 172-80	21
628	FGFR3 mutational status and protein expression in patients with bladder cancer in a Jordanian population. <b>2010</b> , 34, 724-32	28



627	Expression and biological-clinical significance of hTR, hTERT and CKS2 in washing fluids of patients with bladder cancer. <b>2010</b> , 10, 17	9
626	Critical evaluation of vinflunine in the treatment of refractory metastatic urothelial carcinoma. <b>2010</b> , Volume 2, 99-108	
625	A case of Pott's disease with epidural abscess and probable cerebral tuberculoma following Bacillus Calmette-Guérin therapy for superficial bladder cancer. <b>2010</b> , 21, e75-8	15
624	Is repeat transurethral resection effective and necessary in patients with T1 bladder carcinoma?. <b>2010</b> , 85, 276-80	13
623	High-magnification vascular imaging to reject false-positive sites in situ during Hexvix® fluorescence cystoscopy. <b>2010</b> , 15, 051606	6
622	Bladder Cancer Working Group report. <b>2010</b> , 40 Suppl 1, i57-64	54
621	Exon 2 methylation inhibits hepaCAM expression in transitional cell carcinoma of the bladder. <b>2010</b> , 85, 347-54	10
620	Cyclin D1 G870A polymorphism is associated with risk and clinicopathologic characteristics of bladder cancer. <b>2010</b> , 29, 611-7	27
619	Cell cycle arrest and apoptosis in TP53 subtypes of bladder carcinoma cell lines treated with cisplatin and gemcitabine. <b>2010</b> , 235, 814-24	33
618	Impact of prostate cancer multifocality on its biology and treatment. <b>2010</b> , 24, 799-804	33
617	Optimal timing of radical cystectomy in T1 high-grade bladder cancer. <b>2010</b> , 10, 1891-902	6
616	Latest developments in imaging of bladder cancer. <b>2010</b> , 10, 881-94	2
615	Diagnostic random bladder biopsies: reflections from a population-based cohort of 538 patients. <b>2010</b> , 44, 11-9	16
614	Preventive but not curative efficacy of celecoxib on bladder carcinogenesis in a rat model. <b>2010</b> , 2010, 380937	11
613	An improved orthotopic rat bladder tumor model using Dil-loaded fluorescent AY-27 cells. <b>2010</b> , 9, 986-93	8
612	Surgical oncology. Alternatives to surgery after failure of instillation therapy. <b>2010</b> , 7, 307-8	1
611	Fluorescence of the bladder washout fluid following cystoscopy: a preliminary study. <b>2010</b> ,	1
610	The feasibility of real-time bladder mapping using a stereotactic navigational system. <b>2010</b> ,	

609	Update on intravesical agents for non-muscle-invasive bladder cancer. <b>2010</b> , 2, 381-92		14
608	[Diagnosis of and therapy for non-muscle-invasive bladder cancer - state of the art]. <b>2010</b> , 41, 307-15		0
607	Bacillus Calmette-Guérin with or without interferon $\beta$ and megadose versus recommended daily allowance vitamins during induction and maintenance intravesical treatment of nonmuscle invasive bladder cancer. <b>2010</b> , 184, 1915-9		95
606	[Laparoscopic radical cystectomy in elderly patients with bladder cancer: feasibility and evaluation of morbidity]. <b>2010</b> , 20, 204-9		4
605	[Checkup and management of upper urinary tract tumours in 2010: An update from the committee of cancer from the French National Association of Urology]. <b>2010</b> , 20, 260-71		17
604	Serum and tissue profiling in bladder cancer combining protein and tissue arrays. <b>2010</b> , 9, 164-73		29
603	Imaging in bladder cancer: present role and future perspectives. <b>2010</b> , 85, 373-80		24
602	Intravesical therapy for bladder cancer. <b>2010</b> , 11, 947-58		36
601	Developments in intravesical therapy for non-muscle-invasive bladder cancer. <b>2010</b> , 10, 1903-16		7
600	Cystectomy in patients with spinal cord injury: indications and long-term outcomes. <b>2010</b> , 184, 92-8		12
599	Incidences of kidney, pelvis, ureter, and bladder cancer in a nationwide, population-based cancer registry, Denmark, 1944-2003. <i>Urology</i> , <b>2010</b> , 75, 1222-7	1.6	12
598	Quantitative loss of heterozygosity analysis for urothelial carcinoma detection and prognosis. <i>Urology</i> , <b>2010</b> , 76, 515.e1-7	1.6	3
597	Prostate-sparing cystectomy for bladder cancer: a step toward a dead-end. <i>Urology</i> , <b>2010</b> , 76, 260-3	1.6	5
596	Editorial comment. <i>Urology</i> , <b>2010</b> , 76, 263-4; discussion 264	1.6	0
595	HAL blue-light cystoscopy in high-risk nonmuscle-invasive bladder cancer--re-TURBT recurrence rates in a prospective, randomized study. <i>Urology</i> , <b>2010</b> , 76, 664-9	1.6	40
594	Reply. <i>Urology</i> , <b>2010</b> , 76, 264	1.6	0
593	The origins of urothelial carcinoma. <b>2010</b> , 10, 865-80		60
592	Staging and Staging Errors in Bladder Cancer. <b>2010</b> , 9, 2-9		45

591	Hybrid Artificial Intelligence Systems. <b>2010,</b>		1
590	[Pathologic diagnosis and management of flat lesions of urothelium detected with aminolevulinic acid (Hexvix®)]. <b>2011,</b> 21, 157-65		1
589	Early Re-Resection for T1 Transitional Cell Carcinoma of the Bladder: A Study of Current Practice in the South West of England. <b>2011,</b> 4, 18-23		1
588	Multiplexed methylation profiles of tumor suppressor genes in bladder cancer. <b>2011,</b> 13, 29-40		38
587	Practical Urology: Essential Principles and Practice. <b>2011,</b>		9
586	HMOX1 is an important prognostic indicator of nonmuscle invasive bladder cancer recurrence and progression. <b>2011,</b> 185, 701-5		25
585	KISS1 methylation and expression as tumor stratification biomarkers and clinical outcome prognosticators for bladder cancer patients. <b>2011,</b> 179, 540-6		39
584	Bladder cancer: translating molecular genetic insights into clinical practice. <b>2011,</b> 42, 455-81		149
583	Bladder recurrence after surgery for upper urinary tract urothelial cell carcinoma: frequency, risk factors, and surveillance. <b>2011,</b> 29, 130-6		108
582	Recognition and treatment of BCG failure in bladder cancer. <b>2011,</b> 11, 602-13		22
581	Urinary bladder masses: techniques, imaging spectrum, and staging. <b>2011,</b> 35, 411-24		16
580	High magnification cystoscopy in the primary diagnosis of bladder tumors. <i>Current Opinion in Urology,</i> <b>2011,</b> 21, 398-402	2.8	9
579	Management of elderly patients with advanced infiltrating and metastatic bladder cancer: an oncogeriatric approach. <b>2011,</b> 7, 491-502		
578	Inhibition of bladder tumour growth by sirolimus in an experimental carcinogenesis model. <b>2011,</b> 107, 135-43		11
577	Loss of androgen receptor expression is not associated with pathological stage, grade, gender or outcome in bladder cancer: a large multi-institutional study. <b>2011,</b> 108, 24-30		90
576	Use of fluorescein isothiocyanate-human serum albumin for the intravesical photodiagnosis of non-muscle-invasive bladder cancer: an in vitro study using multicellular spheroids composed of normal human urothelial and urothelial cell carcinoma cell lines. <b>2011,</b> 108, 455-9		0
575	Immunohistochemical biomarkers for bladder cancer prognosis. <b>2011,</b> 18, 616-29		42
574	The clinical significance of class III (suspicious) urine cytology. <b>2011,</b> 22, 329-33		10

573	Bladder preservation by concurrent chemoradiation for muscle-invasive bladder cancer: Applicability in low-income countries. <b>2011</b> , 16, 178-83	4
572	Evaluation of the methylation status of tumour suppressor genes for predicting bacillus Calmette-Guérin response in patients with T1G3 high-risk bladder tumours. <b>2011</b> , 60, 131-40	66
571	Long-term cancer-specific survival in patients with high-risk, non-muscle-invasive bladder cancer and tumour progression: a systematic review. <b>2011</b> , 60, 493-500	183
570	Smoking status is a risk factor for recurrence after transurethral resection of non-muscle-invasive bladder cancer. <b>2011</b> , 60, 713-20	66
569	Incidence of malignancy in patients treated for antineutrophil cytoplasm antibody-associated vasculitis: follow-up data from European Vasculitis Study Group clinical trials. <b>2011</b> , 70, 1415-21	104
568	Contemporary use of perioperative cisplatin-based chemotherapy in patients with muscle-invasive bladder cancer. <b>2011</b> , 117, 276-82	104
567	Expression of genes related to apoptosis, cell cycle and signaling pathways are independent of TP53 status in urinary bladder cancer cells. <b>2011</b> , 38, 4159-70	17
566	Long-term experience with early single mitomycin C instillations in patients with low-risk non-muscle-invasive bladder cancer: prospective, single-centre randomised trial. <b>2011</b> , 29, 517-21	28
565	The high incidence of JC virus infection in urothelial carcinoma tissue in Taiwan. <b>2011</b> , 83, 2191-9	14
564	A multicolor fluorescence in situ hybridization assay: A monitoring tool in the surveillance of patients with a history of non-muscle-invasive urothelial cell carcinoma: A prospective study. <b>2011</b> , 119, 395-403	17
563	Incidence and predictors of urotoxic adverse events in cyclophosphamide-treated patients with systemic necrotizing vasculitides. <b>2011</b> , 63, 1435-45	58
562	Exploring liquid chromatography-mass spectrometry fingerprints of urine samples from patients with prostate or urinary bladder cancer. <b>2011</b> , 108, 33-48	15
561	Factors affecting valrubicin response in patients with bacillus Calmette-Guérin-refractory bladder carcinoma in situ. <b>2011</b> , 123, 28-34	9
560	Repeated white light transurethral resection of the bladder in nonmuscle-invasive urothelial bladder cancers: systematic review and meta-analysis. <b>2011</b> , 25, 1703-12	30
559	Lower risk in parous women suggests that hormonal factors are important in bladder cancer etiology. <b>2011</b> , 20, 1156-70	39
558	Management of invasive bladder cancer in patients who are not candidates for or decline cystectomy. <b>2011</b> , 3, 107-17	16
557	Virtual cystoscopy: the evaluation of bladder lesions with computed tomographic virtual cystoscopy. <b>2011</b> , 5, 34-7	12
556	Discussion on the influence of HER2 status on the clinical outcome of bladder cancer continues. <b>2011</b> , 11, 853-8	6

555	Management of Bladder Cancer following Solid Organ Transplantation. <b>2011</b> , 2011, 256985		19
554	Can tissue microarray-based analysis of protein expression predict recurrence of stage Ta bladder cancer?. <b>2011</b> , 45, 270-7		11
553	Modified full-field optical coherence tomography: A novel tool for rapid histology of tissues. <b>2011</b> , 2, 28		44
552	Chemopreventive efficacy of Atorvastatin against nitrosamine-induced rat bladder cancer: antioxidant, anti-proliferative and anti-inflammatory properties. <b>2012</b> , 13, 8482-99		25
551	The effect of gender on oncological outcomes in patients who have undergone radical cystectomy due to bladder cancer. <b>2012</b> , 38, 126-131		
550	Progress in personalizing chemotherapy for bladder cancer. <b>2012</b> , 2012, 364919		15
549	Prolonged retention and in vivo evaluation of cationic nanoparticles loaded with Mitomycin C designed for intravesical chemotherapy of bladder tumours. <b>2012</b> , 29, 576-82		19
548	Unique diagnostic and therapeutic roles of porphyrins and phthalocyanines in photodynamic therapy, imaging and theranostics. <b>2012</b> , 2, 916-66		410
547	Urinary bladder cancer: role of MR imaging. <b>2012</b> , 32, 371-87		106
546	The ubiquitin-specific protease USP2a enhances tumor progression by targeting cyclin A1 in bladder cancer. <i>Cell Cycle</i> , <b>2012</b> , 11, 1123-30	4-7	56
545	Combination of a fusogenic glycoprotein, pro-drug activation and oncolytic HSV as an intravesical therapy for superficial bladder cancer. <b>2012</b> , 106, 496-507		25
544	Intracutaneous and intravesical immunotherapy with keyhole limpet hemocyanin compared with intravesical mitomycin in patients with non-muscle-invasive bladder cancer: results from a prospective randomized phase III trial. <b>2012</b> , 30, 2273-9		33
543	Recurrence and progression in non-muscle-invasive bladder cancer using EORTC risk tables. <b>2012</b> , 89, 61-6		19
542	Surveillance and treatment of non-muscle-invasive bladder cancer in the USA. <b>2012</b> , 2012, 421709		26
541	A novel gene expression system for detecting viable bladder cancer cells. <b>2012</b> , 41, 135-40		4
540	Accurate risk assessment of patients with asymptomatic hematuria for the presence of bladder cancer. <b>2012</b> , 30, 847-52		18
539	Alloplastic bladder substitution: are we making progress?. <b>2012</b> , 44, 1295-303		9
538	Phase 2 study of adjuvant intravesical instillations of apaziquone for high risk nonmuscle invasive bladder cancer. <b>2012</b> , 187, 1195-9		28

537	Increased EZH2 protein expression is associated with invasive urothelial carcinoma of the bladder. <b>2012</b> , 30, 428-33	42
536	Combining molecular and pathologic data to prognosticate non-muscle-invasive bladder cancer. <b>2012</b> , 30, 518-23	28
535	Sarcomatoid Carcinoma (Carcinosarcoma). <b>2012</b> , 355-381	
534	[Muscularis mucosae invasion: prognostic factor for intravesical BCG immunotherapy failure for T1 bladder carcinoma]. <b>2012</b> , 22, 284-90	7
533	Effects of radiation and lifestyle factors on risks of urothelial carcinoma in the Life Span Study of atomic bomb survivors. <b>2012</b> , 178, 86-98	19
532	The orthotopic Fischer/AY-27 rat bladder urothelial cell carcinoma model to test the efficacy of different apaziquone formulations. <b>2012</b> , 30, 64-8	3
531	miR-143, miR-222, and miR-452 are useful as tumor stratification and noninvasive diagnostic biomarkers for bladder cancer. <b>2012</b> , 180, 1808-15	126
530	Radiologic imaging of patients with bladder cancer. <b>2012</b> , 39, 543-58	9
529	Bladder Cancer: General Features. <b>2012</b> , 137-159	2
528	[A second transurethral resection could be not necessary in all high grade non-muscle-invasive bladder tumors]. <b>2012</b> , 36, 539-44	15
527	A multigene urine test for the detection and stratification of bladder cancer in patients presenting with hematuria. <b>2012</b> , 188, 741-7	105
526	Imaging features of common and uncommon bladder neoplasms. <b>2012</b> , 50, 301-16, vi	12
525	A second transurethral resection could be not necessary in all high grade non-muscle-invasive bladder tumors. <b>2012</b> , 36, 539-544	3
524	Handling and Reporting of Bladder Specimens. <b>2012</b> , 525-544	1
523	Tissue-based Biomarkers. <b>2012</b> , 679-706	
522	Molecular Pathology of Bladder Cancer. <b>2012</b> , 707-733	
521	Selective sampling using confocal Raman spectroscopy provides enhanced specificity for urinary bladder cancer diagnosis. <b>2012</b> , 404, 3091-9	43
520	HSD3B and gene-gene interactions in a pathway-based analysis of genetic susceptibility to bladder cancer. <b>2012</b> , 7, e51301	14

519	Prognostic Significance of Substaging according to the Depth of Lamina Propria Invasion in Primary T1 Transitional Cell Carcinoma of the Bladder. <b>2012</b> , 53, 317-23	21
518	Inhibition of bladder tumor growth by chitooligosaccharides in an experimental carcinogenesis model. <b>2012</b> , 10, 2661-75	37
517	Role of screening in urological malignancies. <b>2012</b> , 3, 27-32	
516	A clinical analysis and prognostic study of 62 cases with T1G3 urothelial carcinoma of the bladder. <b>2012</b> , 11, 233-236	1
515	A new and highly prognostic system to discern T1 bladder cancer substage. <b>2012</b> , 61, 378-84	117
514	DDX39 acts as a suppressor of invasion for bladder cancer. <b>2012</b> , 103, 1363-9	22
513	HR-MAS NMR tissue metabolomic signatures cross-validated by mass spectrometry distinguish bladder cancer from benign disease. <b>2013</b> , 12, 3519-28	42
512	Characterization of texture features of bladder carcinoma and the bladder wall on MRI: initial experience. <b>2013</b> , 20, 930-8	30
511	Methylation of a novel panel of tumor suppressor genes in urine moves forward noninvasive diagnosis and prognosis of bladder cancer: a 2-center prospective study. <b>2013</b> , 190, 723-30	39
510	NMIBC risk calculators: how useful are they for the practicing urologist and how can their clinical utility be improved?. <b>2013</b> , 40, 155-64	6
509	Office-based management of nonmuscle invasive bladder cancer. <b>2013</b> , 40, 473-9	4
508	Bcl-2 family of proteins as therapeutic targets in genitourinary neoplasms. <i>Clinical Genitourinary Cancer</i> , <b>2013</b> , 11, 10-9	3-3 12
507	MR imaging of urinary bladder cancer for T-staging: a review and a pictorial essay of diffusion-weighted imaging. <b>2013</b> , 38, 1299-309	45
506	Overexpression of YAP 1 contributes to progressive features and poor prognosis of human urothelial carcinoma of the bladder. <b>2013</b> , 13, 349	80
505	Identification of prefoldin amplification (1q23.3-q24.1) in bladder cancer using comparative genomic hybridization (CGH) arrays of urinary DNA. <b>2013</b> , 11, 182	20
504	MicroRNA-124-3p inhibits cell migration and invasion in bladder cancer cells by targeting ROCK1. <b>2013</b> , 11, 276	90
503	Personalized medicine for targeted and platinum-based chemotherapy of lung and bladder cancer. <b>2013</b> , 5, 369-91	49
502	Pathology of flat bladder lesions with emphasis on putative precursors. <b>2013</b> , 19, 355-365	2

501	MicroRNA-133 inhibits cell proliferation, migration and invasion by targeting epidermal growth factor receptor and its downstream effector proteins in bladder cancer. <b>2013</b> , 47, 423-32	66
500	PMN and anti-tumor immunity--the case of bladder cancer immunotherapy. <b>2013</b> , 23, 183-9	29
499	Polyamine-modulated factor-1 methylation predicts Bacillus Calmette-Guérin response in patients with high-grade non-muscle-invasive bladder carcinoma. <b>2013</b> , 63, 364-70	20
498	Primary prevention and early detection of bladder cancer: two main goals for urologists. <b>2013</b> , 63, 242-3	10
497	Tumor-targeting multifunctional micelles for imaging and chemotherapy of advanced bladder cancer. <b>2013</b> , 8, 1239-51	30
496	EGFR 3RTR 774T>C polymorphism contributes to bladder cancer risk. <b>2013</b> , 28, 49-55	9
495	Upper urinary tract urothelial cell carcinoma: location as a predictive factor for concomitant bladder carcinoma. <b>2013</b> , 31, 141-5	78
494	Evaluating the effectiveness of a smoking warning label on raising patient awareness of smoking and bladder cancer. <b>2013</b> , 190, 475-9	6
493	Analysis of radical cystectomy and urinary diversion complications with the Clavien classification system in an Italian real life cohort. <b>2013</b> , 39, 792-8	58
492	Randomized controlled trial of oxybutynin extended release versus placebo for urinary symptoms during intravesical Bacillus Calmette-Guérin treatment. <b>2013</b> , 189, 1268-74	15
491	Intravesical valrubicin in patients with bladder carcinoma in situ and contraindication to or failure after bacillus Calmette-Guérin. <b>2013</b> , 31, 1635-42	92
490	Can we change patient behaviors to improve urological health?. <b>2013</b> , 190, 383-4	
489	Bacillus Calmette-Guérin (BCG) immunotherapy for bladder cancer: current understanding and perspectives on engineered BCG vaccine. <b>2013</b> , 104, 22-7	105
488	Predicting progression of bladder urothelial carcinoma using microRNA expression. <b>2013</b> , 112, 1027-34	32
487	Combined use of fluorescence cystoscopy and cross-polarization OCT for diagnosis of bladder cancer and correlation with immunohistochemical markers. <b>2013</b> , 6, 687-98	18
486	CXCR4-mediated Stat3 activation is essential for CXCL12-induced cell invasion in bladder cancer. <b>2013</b> , 34, 1839-45	22
485	Intravesical chemotherapy plus bacille Calmette-Guérin in non-muscle invasive bladder cancer: a systematic review with meta-analysis. <b>2013</b> , 111, 977-83	36
484	Med19 promotes bone metastasis and invasiveness of bladder urothelial carcinoma via bone morphogenetic protein 2. <b>2013</b> , 17, 259-64	29



483	Role of oestrogen receptors in bladder cancer development. <b>2013</b> , 10, 317-26	47
482	microRNA-125b inhibits cell migration and invasion by targeting matrix metalloproteinase 13 in bladder cancer. <b>2013</b> , 5, 829-834	43
481	Clinical implications of current developments in genitourinary pathology. <b>2013</b> , 137, 887-93	8
480	Synergistic effect between cisplatin and sunitinib malate on human urinary bladder-cancer cell lines. <b>2013</b> , 2013, 791406	13
479	Omega-3 fatty acids inhibit tumor growth in a rat model of bladder cancer. <b>2013</b> , 2013, 368178	18
478	Detection bias and overestimation of bladder cancer risk in type 2 diabetes: a matched cohort study. <b>2013</b> , 36, 3070-5	22
477	Comparison of the safety and efficacy of conventional monopolar and 2-micron laser transurethral resection in the management of multiple nonmuscle-invasive bladder cancer. <b>2013</b> , 41, 984-92	46
476	Evaluation of open and laparoscopic radical cystoprostatectomy combined with orthotopic neobladder: a single-surgeon experience. <b>2013</b> , 90, 348-53	7
475	Diphtheria toxin-epidermal growth factor fusion protein DAB389EGF for the treatment of bladder cancer. <b>2013</b> , 19, 148-57	36
474	An interobserver reproducibility study on invasiveness of bladder cancer using virtual microscopy and heatmaps. <b>2013</b> , 63, 756-66	30
473	Smoking is associated with lower age, higher grade, higher stage, and larger size of malignant bladder tumors at diagnosis. <b>2013</b> , 133, 446-54	32
472	Prognostic significance of Bcl-xL expression and efficacy of Bcl-xL targeting therapy in urothelial carcinoma. <b>2013</b> , 108, 2312-20	20
471	Diagnostic utility of androgen receptor expression in discriminating poorly differentiated urothelial and prostate carcinoma. <b>2013</b> , 66, 779-86	17
470	Oncogenic activation of Pak1-dependent pathway of macropinocytosis determines BCG entry into bladder cancer cells. <b>2013</b> , 73, 1156-67	68
469	Role of immediate radical cystectomy in the treatment of patients with residual T1 bladder cancer on restaging transurethral resection. <b>2013</b> , 112, 54-9	18
468	Interleukin-11, an interleukin-6-like cytokine, is a promising predictor for bladder cancer prognosis. <b>2013</b> , 7, 684-8	14
467	Bladder cancer epidemiology and genetic susceptibility. <b>2013</b> , 27, 170-8	32
466	Update on the management of non-muscle invasive bladder cancer. <b>2010</b> , 4, 56-64	62

465	Canadian guidelines for treatment of non-muscle invasive bladder cancer: a focus on intravesical therapy. <b>2013</b> , 4, 168	
464	Real-time bladder lesion registration and navigation: a phantom study. <b>2013</b> , 8, e54348	7
463	Gene expression profile and enrichment pathways in different stages of bladder cancer. <b>2013</b> , 12, 1479-89	42
462	Correlation of tumor relapse and elevated expression of survivin and vascular endothelial growth factor in superficial bladder transitional cell carcinoma. <b>2013</b> , 12, 1045-53	15
461	Genetic Instability in Normal-Appearing and Tumor Urothelium Cells and the Role of the TP53 Gene in the Toxicogenomic Effects of Antineoplastic Drugs. <b>2013</b> ,	
460	The Changing Incidence of Carcinoma In-Situ of the Bladder Worldwide. <b>2013</b> ,	
459	Surgical management of bladder transitional cell carcinoma in a vesicular diverticulum: case report. <b>2013</b> , 5, 60	
458	NMP22 is predictive of recurrence in high-risk superficial bladder cancer patients. <b>2009</b> , 3, 454-8	12
457	Risk prediction scores for recurrence and progression of non-muscle invasive bladder cancer: an international validation in primary tumours. <b>2014</b> , 9, e96849	34
456	Is bladder tumor location associated with prostate cancer detection after intravesical bacillus Calmette-Guérin instillation?. <b>2014</b> , 9, e103791	1
455	Detection of tumor-associated antigens in culture supernatants using autoantibodies in sera from patients with bladder cancer. <b>2014</b> , 35, 25-35	18
454	Preoperative T staging of urinary bladder cancer: efficacy of stalk detection and diagnostic performance of diffusion-weighted imaging at 3T. <b>2014</b> , 13, 175-81	26
453	Current Evidence for the Treatment of Bladder Cancer. <b>2014</b> , 37, 1	1
452	[Oncological diseases and postoperative alterations of the bladder and urinary tract]. <b>2014</b> , 54, 1221-34; quiz 1235-6	
451	The feasibility of radical cystectomy in elderly patients. <b>2014</b> , 40, 9-14	2
450	Artesunate induces apoptosis of bladder cancer cells by miR-16 regulation of COX-2 expression. <b>2014</b> , 15, 14298-312	35
449	Saudi oncology society and Saudi urology association combined clinical management guidelines for urothelial urinary bladder cancer. <b>2014</b> , 6, 273-7	1
448	Eosinophilia in routine blood samples as a biomarker for solid tumor development - A study based on the Copenhagen Primary Care Differential Count (CopDiff) Database. <b>2014</b> , 53, 1245-50	5

447	Differentially expressed genes and interacting pathways in bladder cancer revealed by bioinformatic analysis. <b>2014</b> , 10, 1746-52			6
446	Resveratrol induces apoptosis of bladder cancer cells via miR-21 regulation of the Akt/Bcl-2 signaling pathway. <b>2014</b> , 9, 1467-73			47
445	Body mass and smoking are modifiable risk factors for recurrent bladder cancer. <b>2014</b> , 120, 408-14			56
444	Theoretical study on the reaction mechanism of chlordimeform with OH radicals. <b>2014</b> , 20, 2519			0
443	Molecular diagnostic testing of cytology specimens: current applications and future considerations. <b>2014</b> , 3, 280-294			7
442	Stage, grade and pathological characteristics of bladder cancer in the UK: British Association of Urological Surgeons (BAUS) urological tumour registry. <b>2014</b> , 113, 924-30			30
441	Microarray gene expression profiling and analysis of bladder cancer supports the sub-classification of T1 tumours into T1a and T1b stages. <b>2014</b> , 113, 333-42			15
440	[Infectious diseases and injuries of bladder and urinary tract]. <b>2014</b> , 54, 1111-22; quiz 1123-4			
439	Endoscopic molecular imaging of human bladder cancer using a CD47 antibody. <b>2014</b> , 6, 260ra148			92
438	Biomarkers in bladder cancer: translational and clinical implications. <b>2014</b> , 89, 73-111			75
437	Insulin-like growth factor-1 receptor overexpression is associated with outcome in invasive urothelial carcinoma of urinary bladder: a retrospective study of patients treated using radical cystectomy. <i>Urology</i> , <b>2014</b> , 83, 1444.e1-6	1.6		12
436	Urine as a source for clinical proteome analysis: from discovery to clinical application. <b>2014</b> , 1844, 884-98			70
435	Expression of p53 family genes in urinary bladder cancer: correlation with disease aggressiveness and recurrence. <b>2014</b> , 35, 2481-9			10
434	Prognostic comparison of proliferation markers and World Health Organization 1973/2004 grades in urothelial carcinomas of the urinary bladder. <b>2014</b> , 45, 1496-503			13
433	Methylation of tumor suppressor genes in a novel panel predicts clinical outcome in paraffin-embedded bladder tumors. <b>2014</b> , 35, 5777-86			22
432	Cell cycle kinetics, apoptosis rates, DNA damage and TP53 gene expression in bladder cancer cells treated with allyl isothiocyanate (mustard essential oil). <b>2014</b> , 762, 40-6			31
431	MR imaging of the urinary bladder. <b>2014</b> , 22, 129-34, v			6
430	Significance of positive urine cytology on progression and cancer-specific mortality of non-muscle-invasive bladder cancer. <i>Clinical Genitourinary Cancer</i> , <b>2014</b> , 12, e87-93	3.3		9

429	Long-term survival in bone-predominant metastatic urothelial carcinoma. <i>Clinical Genitourinary Cancer</i> , <b>2014</b> , 12, e241-4	3-3	4
428	Confocal laser endomicroscopy of bladder and upper tract urothelial carcinoma: a new era of optical diagnosis?. <b>2014</b> , 15, 437		39
427	ARID1A immunohistochemistry improves outcome prediction in invasive urothelial carcinoma of urinary bladder. <b>2014</b> , 45, 2233-9		23
426	Neoadjuvante chemotherapie voor het spierinvasief urotheelcelcarcinoom van de blaas: een landelijke inventarisatie. <b>2014</b> , 4, 50-56		
425	Landmarks in non-muscle-invasive bladder cancer. <b>2014</b> , 11, 476-80		20
424	Multimodal management of muscle-invasive bladder cancer. <b>2014</b> , 38, 80-108		45
423	Urinary cell-free microRNA-106b as a novel biomarker for detection of bladder cancer. <b>2014</b> , 31, 197		30
422	Diagnostic utility of p53 and CK20 immunohistochemical expression grading urothelial malignancies. <b>2014</b> , 7, 36		16
421	Impaired estimated glomerular filtration rate is a significant predictor for non-muscle-invasive bladder cancer recurrence and progression--introducing a novel prognostic model for bladder cancer recurrence. <b>2014</b> , 32, 1178-83		28
420	A floating hydrogel system capable of generating CO2 bubbles to diminish urinary obstruction after intravesical instillation. <b>2014</b> , 31, 2655-63		16
419	Recent advances in imaging cancer of the kidney and urinary tract. <b>2014</b> , 23, 863-910		19
418	Polyclonal antibody from 47 kDa protein of bladder cancer is sensitive and specific for detection of bladder cancer. <b>2014</b> , 6, 116-120		2
417	Intravesical instillation of c-MYC inhibitor KSI-3716 suppresses orthotopic bladder tumor growth. <b>2014</b> , 191, 510-8		40
416	Role of microRNA-27a in down-regulation of angiogenic factor AGGF1 under hypoxia associated with high-grade bladder urothelial carcinoma. <b>2014</b> , 1842, 712-25		40
415	Examining the management of muscle-invasive bladder cancer by medical oncologists in the United States. <b>2014</b> , 32, 637-44		41
414	Intravaginal and subcutaneous immunization induced vaccine specific CD8 T cells and tumor regression in the bladder. <b>2014</b> , 191, 814-22		12
413	Impact of bladder neck involvement on progression in patients with primary non-muscle invasive bladder cancer: a prospective validation study. <b>2014</b> , 32, 38.e29-36		14
412	Role of osteopontin in the regulation of human bladder cancer proliferation and migration in T24 cells. <b>2015</b> , 11, 3701-7		11

411	The effectiveness of BCG and interferon against non-muscle invasive bladder cancer: a New Zealand perspective. <b>2015</b> , 116 Suppl 3, 54-60		4
410	Körperstereotaxie bei urologischen Tumoren. <b>2015</b> , 18, 54-62		
409	Prognostic significance of substage and WHO classification systems in T1 urothelial carcinoma of the bladder. <i>Current Opinion in Urology</i> , <b>2015</b> , 25, 427-35	2.8	20
408	Lipid Metabolism Profiling and Bladder Cancer. <b>2015</b> , 05,		0
407	The characteristics of recurrent upper tract urothelial carcinoma after radical nephroureterectomy without bladder cuff excision. <b>2015</b> , 56, 375-81		10
406	Evaluation of different p16 immunostaining methods and the prognostic role of p16/Ki-67 combined expression in non-muscle invasive bladder cancers. <b>2015</b> , 66, 57-66		3
405	Attenuated XPC expression is not associated with impaired DNA repair in bladder cancer. <b>2015</b> , 10, e0126029		8
404	Development and Characterization of Bladder Cancer Patient-Derived Xenografts for Molecularly Guided Targeted Therapy. <b>2015</b> , 10, e0134346		56
403	Can CT Virtual Cystoscopy Replace Conventional Cystoscopy in Early Detection of Bladder Cancer?. <b>2015</b> , 2015, 926590		3
402	Bladder carcinoma data with clinical risk factors and molecular markers: a cluster analysis. <b>2015</b> , 2015, 168682		31
401	Sex differences in bladder cancer pathology and survival: analysis of a population-based cancer registry. <b>2015</b> , 4, 363-70		29
400	Circulating microRNAs in Disease Diagnostics and their Potential Biological Relevance. <b>2015</b> ,		7
399	Large bowel obstruction resulting from bladder transitional cell carcinoma metastasis: a common cancer presenting in an uncommon manner. <b>2015</b> , 2015,		1
398	Management of carcinoma in situ of the bladder: best practice and recent developments. <b>2015</b> , 7, 351-64		28
397	Smoking and Bladder Cancer: A Systematic Review of Risk and Outcomes. <b>2015</b> , 1, 17-27		57
396	Vascular endothelial growth factor mRNA levels as a biomarker for short-term N-butyl-N-(4-hydroxybutyl) nitrosamine-induced rat bladder carcinogenesis bioassay. <b>2015</b> , 35, 181-90		
395	Treatment and management of high-grade T1 bladder cancer: what should we do after second TUR?. <b>2015</b> , 45, 315-22		12
394	Expression of tumor suppressive microRNA-34a is associated with a reduced risk of bladder cancer recurrence. <b>2015</b> , 137, 1158-66		30

393	Diagnosis and management of urothelial carcinoma in situ of the lower urinary tract: a systematic review. <b>2015</b> , 67, 876-88	50
392	Downregulation of SKA1 Gene Expression Inhibits Cell Growth in Human Bladder Cancer. <b>2015</b> , 30, 271-7	19
391	Upregulation of the B7/CD28 family member B7-H3 in bladder cancer. <b>2015</b> , 9, 1420-1424	8
390	Nanotechnology in bladder cancer: current state of development and clinical practice. <b>2015</b> , 10, 1189-201	28
389	Advances in imaging technologies in the evaluation of high-grade bladder cancer. <b>2015</b> , 42, 147-57, vii	34
388	Cancers urologiques en Alg�e : profil histopathologique propos de 348 cas. <b>2015</b> , 7, 126-131	2
387	TRPM2 mediates histone deacetylase inhibition-induced apoptosis in bladder cancer cells. <b>2015</b> , 30, 87-93	17
386	Localized Surgical Therapy and Surveillance. <b>2015</b> , 179-190	
385	HPLC assisted Raman spectroscopic studies on bladder cancer. <b>2015</b> , 12, 045701	6
384	Role of Narrow Band Imaging in Management of Urothelial Carcinoma. <b>2015</b> , 16, 58	8
383	Local immunostimulation recruits vaccine-specific CD8 T cells and increases regression of bladder tumor. <b>2015</b> , 4, e1016697	10
382	Review: Application of Nanoparticles in Urothelial Cancer of the Urinary Bladder. <b>2015</b> , 35, 419-427	19
381	Assess the expression of ubiquitin specific protease USP2a for bladder cancer diagnosis. <b>2015</b> , 15, 80	8
380	Muscle-invasive bladder cancer is characterized by overexpression of thymidine kinase 1. <b>2015</b> , 33, 426.e21-9	3
379	Tapping botanicals for essential oils: Progress and hurdles in cancer mitigation. <b>2015</b> , 76, 1148-1163	15
378	World Urologic Oncology Federation Bladder Cancer Prevention Program: a global initiative. <b>2015</b> , 33, 25-29	24
377	A sensitive and selective magnetic graphene composite-modified polycrystalline-silicon nanowire field-effect transistor for bladder cancer diagnosis. <b>2015</b> , 66, 198-207	41
376	Rare Tumors and Tumor-like Conditions in Urological Pathology. <b>2015</b> ,	2

375	Management of Bladder Cancer. <b>2015</b> ,		1
374	Dynamics of Cancer-Related Proteins in Patients with Bladder Cancer. <b>2016</b> ,		
373	Non-muscle invasive high grade urothelial carcinoma of the bladder. Which factors can influence understaging at the time of radical cystectomy?. <b>2016</b> , 88, 13-6		8
372	Fluorescence Cystoscopy. <b>2016</b> , 25-63		1
371	Molecular targets in urothelial cancer: detection, treatment, and animal models of bladder cancer. <b>2016</b> , 10, 3305-3322		20
370	Photo-thermal therapy of bladder cancer with Anti-EGFR antibody conjugated gold nanoparticles. <b>2016</b> , 21, 1211-21		16
369	Parity, Age at First Birth, and Risk of Death from Bladder Cancer: A Population-Based Cohort Study in Taiwan. <b>2016</b> , 13,		3
368	Increasing Disadvantages in Cancer Survival in New Zealand Compared to Australia, between 2000-05 and 2006-10. <b>2016</b> , 11, e0150734		9
367	A Multimodal Imaging Approach for Longitudinal Evaluation of Bladder Tumor Development in an Orthotopic Murine Model. <b>2016</b> , 11, e0161284		10
366	The value of extensive transurethral resection in the diagnosis and treatment of nonmuscle invasive bladder cancer with respect to recurrence at the first follow-up cystoscopy. <i>OncoTargets and Therapy</i> , <b>2016</b> , 9, 2019-25	4.4	2
365	Complications and quality of life in elderly patients with several comorbidities undergoing cutaneous ureterostomy with single stoma or ileal conduit after radical cystectomy. <b>2016</b> , 118, 521-6		36
364	Biomarkers in bladder cancer: A metabolomic approach using in vitro and ex vivo model systems. <b>2016</b> , 139, 256-68		49
363	Monitoring and malignancy concerns in patients with congenital bladder anomalies. <i>Current Opinion in Urology</i> , <b>2016</b> , 26, 344-50	2.8	10
362	Bladder Leiomyosarcoma: A Rare, but Aggressive Diagnosis. <b>2016</b> , 9, 166-168		4
361	Intravesical Bacillus Calmette-Guérin with interferon-alpha versus intravesical Bacillus Calmette-Guérin for treating non-muscle-invasive bladder cancer. <b>2016</b> ,		1
360	Bladder cancer prevention program (BCPP): A global initiative. <b>2016</b> , 15, 44-44c		
359	A new non-muscle-invasive bladder tumor-homing peptide identified by phage display in vivo. <b>2016</b> , 36, 79-89		13
358	Quantitative genome-wide methylation analysis of high-grade non-muscle invasive bladder cancer. <b>2016</b> , 11, 237-46		30

357	Prognostic Significance of VEGF after Twenty-Year Follow-up in a Randomized Trial of Fenretinide in Non-Muscle-Invasive Bladder Cancer. <b>2016</b> , 9, 437-44		17
356	Budget impact of incorporating one instillation of hexaminolevulinate hydrochloride blue-light cystoscopy in transurethral bladder tumour resection for patients with non-muscle-invasive bladder cancer in Sweden. <b>2016</b> , 117, E102-13		5
355	Cell-cycle markers do not improve discrimination of EORTC and CUETO risk models in predicting recurrence and progression of non-muscle-invasive high-grade bladder cancer. <b>2016</b> , 34, 485.e7-485.e14		16
354	Clinical predictors for high-grade bladder cancer before first-time transurethral resection of the bladder tumor: a retrospective cohort study. <b>2016</b> , 46, 964-967		4
353	A Comprehensive Investigation toward the Indicative Proteins of Bladder Cancer in Urine: From Surveying Cell Secretomes to Verifying Urine Proteins. <b>2016</b> , 15, 2164-77		11
352	Körperstereotaxie bei urologischen Tumoren. <b>2016</b> , 20, 37-45		
351	Prostate tumor overexpressed 1 expression in invasive urothelial carcinoma. <b>2016</b> , 142, 937-47		7
350	Caractéristiques épidémiologiques du cancer de la vessie chez la femme en Tunisie. <b>2016</b> , 22, 71-75		4
349	Association Between N-acetyltransferase 2 Polymorphism and Bladder Cancer Risk: Results From Studies of the Past Decade and a Meta-Analysis. <i>Clinical Genitourinary Cancer</i> , <b>2016</b> , 14, 122-9	3-3	10
348	Significant Role of Lifetime Cigarette Smoking in Worsening Bladder Cancer and Upper Tract Urothelial Carcinoma Prognosis: A Meta-Analysis. <b>2016</b> , 195, 872-9		30
347	Case Report of a Rare Presentation of Urothelial Carcinoma With Gastric Metastasis. <i>Clinical Genitourinary Cancer</i> , <b>2016</b> , 14, e111-4	3-3	1
346	Overexpression of CIP2A promotes bladder cancer progression by regulating EMT. <b>2016</b> , 18, 289-95		7
345	Clinicopathologic Comparison of Urothelial Bladder Carcinoma in Young and Elder Patients. <b>2016</b> , 22, 67-70		6
344	A phase 2 study of TMX-101, intravesical imiquimod, for the treatment of carcinoma in situ bladder cancer. <b>2017</b> , 35, 39.e1-39.e7		25
343	Liquid Biopsy Analysis of FGFR3 and PIK3CA Hotspot Mutations for Disease Surveillance in Bladder Cancer. <b>2017</b> , 71, 961-969		100
342	The immune infiltrate in prostate, bladder and testicular tumors: An old friend for new challenges. <b>2017</b> , 53, 138-145		15
341	Intravesical Bacillus Calmette-Guérin with interferon-alpha versus intravesical Bacillus Calmette-Guérin for treating non-muscle-invasive bladder cancer. <b>2017</b> , 3, CD012112		15
340	Urothelial carcinoma in first histological diagnosis of patients over 80 years has distinctive histological features: a retrospective single-institution study of 185 patients. <b>2017</b> , 470, 561-565		



339	Low expression of TMEM67 is a critical predictor of poor prognosis in human urothelial carcinoma of the bladder. <b>2017</b> , 35, 152.e7-152.e12	0
338	New developments in the management of nonmuscle invasive bladder cancer. <b>2017</b> , 29, 179-183	
337	Prognostic value of impaired estimated glomerular filtration rate in intravesical BCG-treated non-muscle-invasive bladder cancer patients. <b>2017</b> , 7, 1380	4
336	Contrast-Enhanced Ultrasound Differentiation Between Low- and High- Grade Bladder Urothelial Carcinoma and Correlation With Tumor Microvessel Density. <b>2017</b> , 36, 2287-2297	17
335	Recurrent bladder tumors after transurethral resection: Diagnostic yield of MDCT-virtual cystoscopy. <b>2017</b> , 48, 509-517	
334	Incorporating VEGF-targeted therapy in advanced urothelial cancer. <b>2017</b> , 9, 33-45	11
333	p53 immunohistochemistry in high-grade urothelial carcinoma of the bladder is prognostically significant. <b>2017</b> , 71, 296-304	20
332	Next-generation sequencing of urine specimens: A novel platform for genomic analysis in patients with non-muscle-invasive urothelial carcinoma treated with bacille Calmette-Guérin. <b>2017</b> , 125, 416-426	20
331	Three serum metabolite signatures for diagnosing low-grade and high-grade bladder cancer. <b>2017</b> , 7, 46176	18
330	Biological/pathological functions of the CXCL12/CXCR4/CXCR7 axes in the pathogenesis of bladder cancer. <b>2017</b> , 22, 991-1000	36
329	Optical improvements in the diagnosis of bladder cancer: implications for clinical practice. <b>2017</b> , 9, 251-260	27
328	Curcumin inhibits bladder cancer progression via regulation of E-cadherin expression. <b>2017</b> , 39, 1010428317702548	
327	Association Of Plasma And Urinary Mutant DNA With Clinical Outcomes In Muscle Invasive Bladder Cancer. <b>2017</b> , 7, 5554	51
326	Long-term validation of a molecular progression-associated gene classifier for prediction of muscle invasion in primary non-muscle-invasive bladder cancer. <b>2017</b> , 14, 2468-2474	6
325	Lower tract neoplasm: Update of imaging evaluation. <b>2017</b> , 97, 119-130	8
324	Antitumor effects of curcumin in human bladder cancer. <b>2017</b> , 14, 1157-1161	21
323	Systematic review of bladder cancer outcomes in patients with spina bifida. <b>2017</b> , 13, 456.e1-456.e9	25
322	Clinical outcomes of second transurethral resection in non-muscle invasive high-grade bladder cancer: a retrospective, multi-institutional, collaborative study. <b>2017</b> , 22, 353-358	10

321	Clinical risk stratification in patients with surgically resectable micropapillary bladder cancer. <b>2017</b> , 119, 684-691		24
320	Evaluation of the Efficacy of Solifenacin for Preventing Catheter-Related Bladder Discomfort After Transurethral Resection of Bladder Tumors in Patients With Non-Muscle Invasive Bladder Cancer: A Prospective, Randomized, Multicenter Study. <i>Clinical Genitourinary Cancer</i> , <b>2017</b> , 15, 157-162	3.3	8
319	Clinical significance of incidentally detected bladder wall thickening on computed tomography. <b>2017</b> , 49, 191-196		2
318	miR-5195-3p Inhibits Proliferation and Invasion of Human Bladder Cancer Cells by Directly Targeting Oncogene KLF5. <b>2017</b> , 25, 1081-1087		29
317	Inhibitory effects of resveratrol on the adhesion, migration and invasion of human bladder cancer cells. <b>2017</b> , 15, 885-889		20
316	Bladder Cancer Markers and Recent Innovations. <b>2017</b> ,		1
315	Expression of urinary miRNAs targeting NLRs inflammasomes in bladder cancer. <i>OncoTargets and Therapy</i> , <b>2017</b> , 10, 2665-2673	4.4	38
314	Interleukin-27 augments the inhibitory effects of sorafenib on bladder cancer cells. <b>2017</b> , 50, e6207		6
313	Nonmuscle-invasive bladder cancer: what's changing and what has changed. <b>2017</b> , 84, 1-8		7
312	The landscape of genetics and biomarkers in bladder cancer. <b>2017</b> , 6, 1027-1030		4
311	Is folic acid safe for non-muscle-invasive bladder cancer patients? An evidence-based cohort study. <b>2018</b> , 107, 208-216		12
310	Progression of urothelial carcinoma in situ of the urinary bladder: a switch from luminal to basal phenotype and related therapeutic implications. <b>2018</b> , 472, 749-758		29
309	Unravelling disparate roles of NOTCH in bladder cancer. <b>2018</b> , 15, 345-357		29
308	hTERT mRNA expression in urine as a useful diagnostic tool in bladder cancer. Comparison with cytology and NMP22 BladderCheck Test <sup>®</sup> . <b>2018</b> , 42, 524-530		3
307	A practical guide to bladder cancer pathology. <b>2018</b> , 15, 143-154		24
306	Diagnostic performance of diffusion-weighted MR imaging at 3.0 T in predicting muscle invasion in urinary bladder cancer: utility of evaluating the morphology of the reactive tumor stalk. <b>2018</b> , 43, 2431-2441		4
305	HumanMethylation450K Array-Identified Biomarkers Predict Tumour Recurrence/Progression at Initial Diagnosis of High-risk Non-muscle Invasive Bladder Cancer. <b>2018</b> , 10, 1179299X17751920		8
304	Prediction models for progression of non-muscle-invasive bladder cancer: A review. <b>2018</b> , 25, 212-218		28

303	Is quality of registry treatment data related to registrar experience and workload? A study of Taiwan cancer registry data. <b>2018</b> , 117, 1093-1100		5
302	The role of 3-dimensional sonography and virtual sonographic cystoscopy in detection of bladder tumors. <b>2018</b> , 24, 73-78		1
301	High cytoplasmic HuR expression is associated with advanced pT stage, high grade and increased microvessel density in urothelial bladder carcinoma. <b>2018</b> , 33, 40-44		6
300	Contemporary Patterns of Multidisciplinary Care in Patients With Muscle-invasive Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , <b>2018</b> , 16, 213-218	3.3	10
299	Increased endocytosis of magnetic nanoparticles into cancerous urothelial cells versus normal urothelial cells. <b>2018</b> , 149, 45-59		12
298	Prevalence, management, and prognosis of bladder cancer in patients with neurogenic bladder: A systematic review. <b>2018</b> , 37, 1386-1395		34
297	Evaluation of Urinary DNA Methylation as a Marker for Recurrent Bladder Cancer: A 2-Center Prospective Study. <i>Urology</i> , <b>2018</b> , 113, 71-78	1.6	10
296	Symptoms. <b>2018</b> , 45-55		
295	Tumour front inflammation and necrosis are independent prognostic predictors in high-grade urothelial carcinoma of the bladder. <b>2018</b> , 71, 154-160		14
294	Surveillance for Cancers Associated with Tobacco Use - United States, 2010-2014. <b>2018</b> , 67, 1-42		20
293	Epigenetic silencing of miR-200b is associated with cisplatin resistance in bladder cancer. <b>2018</b> , 9, 24457-24469		17
292	Immunotherapy for Urothelial Carcinoma: Current Evidence and Future Directions. <b>2018</b> , 19, 109		32
291	SNPs and Somatic Mutation on Long Non-Coding RNA: New Frontier in the Cancer Studies?. <b>2018</b> , 7,		29
290	Demographic and Survivorship Disparities in Non-muscle-invasive Bladder Cancer in the United States. <b>2018</b> , 51, 242-247		13
289	P3H4 is correlated with clinicopathological features and prognosis in bladder cancer. <b>2018</b> , 16, 206		4
288	Genitourinary Cancers. <b>2018</b> ,		
287	Optical and Cross-Sectional Imaging Technologies for Bladder Cancer. <b>2018</b> , 175, 139-163		4
286	Overview of Current and Future Adjuvant Therapy for Muscle-Invasive Urothelial Carcinoma. <b>2018</b> , 19, 36		12

285	Histological Classification of Bladder Tumors. <b>2018</b> , 147-180			1
284	ACR Appropriateness Criteria Pretreatment Staging of Muscle-Invasive Bladder Cancer. <b>2018</b> , 15, S150-S159			28
283	Development and external validation of a nomogram to predict high-grade papillary bladder cancer before first-time transurethral resection of the bladder tumor. <b>2018</b> , 23, 957-964			8
282	Melittin Constrains the Expression of Identified Key Genes Associated with Bladder Cancer. <b>2018</b> , 2018, 5038172			7
281	Impact of Occupational Exposures and Genetic Polymorphisms on Recurrence and Progression of Non-Muscle-Invasive Bladder Cancer. <b>2018</b> , 15,			3
280	High-Performance Identification of Human Bladder Cancer Using a Signal Self-Amplifiable Photoacoustic Nanoprobe. <b>2018</b> , 10, 28331-28339			11
279	miR-129-5p inhibits gemcitabine resistance and promotes cell apoptosis of bladder cancer cells by targeting Wnt5a. <b>2018</b> , 50, 1811-1819			23
278	hTERT mRNA expression in urine as a useful diagnostic tool in bladder cancer. Comparison with cytology and NMP22 BladderCheck Test <sup>®</sup> . <b>2018</b> , 42, 524-530			2
277	ARID1A-deficiency in urothelial bladder cancer: No predictive biomarker for EZH2-inhibitor treatment response?. <b>2018</b> , 13, e0202965			16
276	Combination chemotherapy with Zyflamend reduced the acquired resistance of bladder cancer cells to cisplatin through inhibiting NFB signaling pathway. <i>OncoTargets and Therapy</i> , <b>2018</b> , 11, 4413-4429	4.4		4
275	The efficacy and safety of intravesical gemcitabine vs Bacille Calmette-Guérin for adjuvant treatment of non-muscle invasive bladder cancer: a meta-analysis. <i>OncoTargets and Therapy</i> , <b>2018</b> , 11, 4641-4649	4.4		11
274	Bladder Cancer Cell Capture: Elucidating the Effect of Sample Storage Conditions on Capturing Bladder Cancer Cells via Surface Immobilized EpCAM Antibody.. <b>2019</b> , 2, 3730-3736			5
273	Risk Stratification and Prognostication of Bladder Cancer. <b>2019</b> , 423-436			
272	MicroRNA-132 inhibits migration, invasion and epithelial-mesenchymal transition via TGF $\beta$ /Smad2 signaling pathway in human bladder cancer. <i>OncoTargets and Therapy</i> , <b>2019</b> , 12, 5937-5945	4.4		11
271	Evaluation of Gene as a Potential Biomarker for Bladder Cancer. <i>Disease Markers</i> , <b>2019</b> , 2019, 3875147	3.2		1
270	GC-MS Metabolomics Reveals Distinct Profiles of Low- and High-Grade Bladder Cancer Cultured Cells. <b>2019</b> , 9,			8
269	Determinants of Guideline-Based Treatment in Patients With cT1 Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , <b>2019</b> , 17, e461-e471		3.3	8
268	Methods for bladder cancer diagnosis - The role of autofluorescence and photodynamic diagnosis. <b>2019</b> , 27, 141-148			15

267	Quality Control Indicators for Transurethral Resection of Non-Muscle-Invasive Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , <b>2019</b> , 17, e784-e792	3.3	15
266	Immunotherapy in non-metastatic urothelial cancer: back to the future? <b>2019</b> , 19, 685-695		3
265	Low-risk non-muscle-invasive bladder cancer: Further prognostic stratification into the "very-low-risk" group based on tumor size. <b>2019</b> , 26, 481-486		5
264	Targeting amine- and phenol-containing metabolites in urine by dansylation isotope labeling and liquid chromatography mass spectrometry for evaluation of bladder cancer biomarkers. <b>2019</b> , 27, 460-474		6
263	Patients choose certainty over burden in bladder cancer surveillance. <b>2019</b> , 37, 2747-2753		2
262	The role of oncostatin M receptor gene polymorphisms in bladder cancer. <b>2019</b> , 17, 30		7
261	Human epidermal growth factor receptor 2 amplification as a biomarker for treatment in patients with lymph node-metastatic penoscrotal extramammary Paget's disease. <b>2019</b> , 17, 2677-2686		2
260	Integrated Fourier Transform Infrared Imaging and Proteomics for Identification of a Candidate Histochemical Biomarker in Bladder Cancer. <b>2019</b> , 189, 619-631		24
259	Expression of bladder cancer-associated glycans in murine tumor cell lines. <b>2019</b> , 17, 3141-3150		5
258	Variant Histology in Bladder Cancer-Current Understanding of Pathologic Subtypes. <b>2019</b> , 20, 80		4
257	IMP3 is a biomarker for non-muscle-invasive urothelial carcinoma of the bladder associated with an aggressive phenotype. <b>2019</b> , 98, e16009		7
256	Rates of lymph node invasion and their impact on cancer specific mortality in upper urinary tract urothelial carcinoma. <b>2019</b> , 45, 1238-1245		11
255	Immunohistochemical expression of Ki-67, Cyclin D1, p16INK4a, and Survivin as a predictive tool for recurrence and progression-free survival in papillary urothelial bladder cancer pTa / pT1 G2 (WHO 1973). <b>2019</b> , 37, 158-165		3
254	The Feasibility and Safety of Reproductive Organ Preserving Radical Cystectomy for Elderly Female Patients With Muscle-Invasive Bladder Cancer: A Retrospective Propensity Score-matched Study. <i>Urology</i> , <b>2019</b> , 125, 138-145	1.6	6
253	Genomic classification and risk stratification of bladder cancer. <b>2019</b> , 37, 1751-1757		6
252	Molecular characterization of low grade and high grade bladder cancer. <b>2019</b> , 14, e0210635		10
251	Glycoprotein-130 Expression Is Associated with Aggressive Bladder Cancer and Is a Potential Therapeutic Target. <b>2019</b> , 18, 413-420		8
250	T1 bladder cancer: current considerations for diagnosis and management. <b>2019</b> , 16, 23-34		43

249	Expression of TOMM34 and Its Clinicopathological Correlations in Urothelial Carcinoma of the Bladder. <b>2020</b> , 26, 411-418	3
248	Risk Stratification Tools and Prognostic Models in Non-muscle-invasive Bladder Cancer: A Critical Assessment from the European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel. <b>2020</b> , 6, 479-489	39
247	Linear age-course effects on the associations between body mass index, triglycerides, and female breast and male liver cancer risk: An internal replication study of 800,000 individuals. <b>2020</b> , 146, 58-67	6
246	Clinical significance of urothelial carcinoma ambiguous for muscularis propria invasion on initial transurethral resection of bladder tumor. <b>2020</b> , 38, 389-395	1
245	Improving diagnosis of genitourinary cancers: Biomarker discovery strategies through mass spectrometry-based metabolomics. <b>2020</b> , 178, 112905	10
244	Neoplasms of the Urinary Bladder. <b>2020</b> , 230-321.e19	1
243	Carcinoma of the Bladder. <b>2020</b> , 1382-1400.e4	0
242	Impact of Bladder Neck Involvement on Recurrence in Patients With Non-muscle-invasive Bladder Cancer: An Analysis Based on a Time-dependent Model. <i>Clinical Genitourinary Cancer</i> , <b>2020</b> , 18, e62-e70 <sup>3-3</sup>	3
241	Dataset for the reporting of urinary tract carcinoma-biopsy and transurethral resection specimen: recommendations from the International Collaboration on Cancer Reporting (ICCR). <b>2020</b> , 33, 700-712	6
240	The impact of underinsurance on bladder cancer diagnosis, survival, and care delivery for individuals under the age of 65 years. <b>2020</b> , 126, 496-505	9
239	Fluid intake and clinicopathological characteristics of bladder cancer: the West Midlands Bladder Cancer Prognosis Programme. <b>2020</b> , 29, 110-118	
238	Next-Generation Sequencing Reveals Potential Predictive Biomarkers and Targets of Therapy for Urothelial Carcinoma in Situ of the Urinary Bladder. <b>2020</b> , 190, 323-332	13
237	The increased risk for thromboembolism pre-cystectomy in patients undergoing neoadjuvant chemotherapy for muscle-invasive urinary bladder cancer is mainly due to central venous access: a multicenter evaluation. <b>2020</b> , 52, 661-669	3
236	Fewer tumour draining sentinel nodes in patients with progressing muscle invasive bladder cancer, after neoadjuvant chemotherapy and radical cystectomy. <b>2020</b> , 38, 2207-2213	2
235	Osteomyelitis and septic arthritis after Mycobacterium Bovis BCG Therapy for Urinary Bladder Cancer. <b>2020</b> , 68, 179-183	1
234	Can immune markers help identify fast relapse in patients with muscle invasive bladder cancer?. <i>Pathology Research and Practice</i> , <b>2020</b> , 216, 153200	3-4 1
233	Partitioning of time trends in prevalence and mortality of bladder cancer in the United States. <b>2020</b> , 47, 25-29	3
232	Histopathological distinction of non-invasive and invasive bladder cancers using machine learning approaches. <b>2020</b> , 20, 162	5

231	Combined T2 SPAIR, Dynamic Enhancement and DW Imaging Reliably Detect T Staging and Grading of Bladder Cancer With 3.0T MRI. <b>2020</b> , 10, 582532	1
230	Bladder Cancer: A Review. <b>2020</b> , 324, 1980-1991	195
229	Emerging Roles of Urine-Based Tumor DNA Analysis in Bladder Cancer Management. <b>2020</b> , 4,	2
228	Computerized tomography before the final treatment cycle of neoadjuvant chemotherapy or induction chemotherapy in muscle-invasive urinary bladder cancer, cannot predict pathoanatomical outcomes and does not reflect prognosis-results of a single centre retrospective prognostic study. <b>2020</b> , 9, 1062-1072	1
227	Fibroblast Growth Factor Receptor 3 Alteration Status is Associated with Differential Sensitivity to Platinum-based Chemotherapy in Locally Advanced and Metastatic Urothelial Carcinoma. <b>2020</b> , 78, 907-915	9
226	Long-term trends in sex difference in bladder cancer survival 1975-2009: A population-based study in Osaka, Japan. <b>2020</b> , 9, 7330-7340	3
225	-Palmitoylation as a Functional Regulator of Proteins Associated with Cisplatin Resistance in Bladder Cancer. <b>2020</b> , 16, 2490-2505	8
224	Assessing the Impact of the Absence of Detrusor Muscle in Ta Low-grade Urothelial Carcinoma of the Bladder on Recurrence-free Survival. <b>2021</b> , 7, 1324-1331	4
223	In the World of Bladder Tumors: Size Does Matter. <b>2020</b> , 6, 195-200	
222	Lifestyle and Non-muscle Invasive Bladder Cancer Recurrence, Progression, and Mortality: Available Research and Future Directions. <b>2020</b> , 6, 9-23	3
221	Fanconi Anemia Pathway Activation by FOXM1 Is Critical to Bladder Cancer Recurrence and Anticancer Drug Resistance. <b>2020</b> , 12,	8
220	Evaluation of autofluorescence and photodynamic diagnosis in assessment of bladder lesions. <b>2020</b> , 30, 101719	1
219	Expression and Function of Eicosanoid-Producing Cytochrome P450 Enzymes in Solid Tumors. <b>2020</b> , 11, 828	6
218	PD-L1 expression in bladder primary in situ urothelial carcinoma: evaluation in BCG-unresponsive patients and BCG responders. <b>2020</b> , 477, 269-277	7
217	Genitourinary Pathology (Including Adrenal Gland). <b>2020</b> , 1523-1726	
216	Correlation of mismatch repair protein deficiency, PD-L1 and CD8 expression in high-grade urothelial carcinoma of the bladder. <b>2020</b> , 73, 519-522	3
215	Targeted drug delivery systems for bladder cancer therapy. <b>2020</b> , 56, 101535	15
214	Assessment of the clinical efficacy of simultaneous transurethral resection of both bladder cancer and the prostate: a systematic review and meta-analysis. <b>2020</b> , 23, 1182-1193	2

213	A Panel of Urinary Long Non-coding RNAs Differentiate Bladder Cancer from Urocystitis. <b>2020</b> , 11, 781-787	17
212	Differential Expression and Clinicopathological Significance of HER2, Indoleamine 2,3-Dioxygenase and PD-L1 in Urothelial Carcinoma of the Bladder. <b>2020</b> , 9,	7
211	Gene Expression Profiles Identified Novel Urine Biomarkers for Diagnosis and Prognosis of High-Grade Bladder Urothelial Carcinoma. <b>2020</b> , 10, 394	9
210	Quantifying the Overall Survival Benefit With Early Radical Cystectomy for Patients With Histologically Confirmed T1 Non-muscle-invasive Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , <b>2020</b> , 18, e651-e659	3-3 4
209	Effect of adjuvant chemotherapy in locally advanced urothelial carcinoma of the bladder treated with cystectomy. <b>2020</b> , 44, 94-102	0
208	Immune gene expression profiles in high-grade urothelial carcinoma of the bladder: a NanoString study. <b>2021</b> , 74, 53-57	4
207	Comparison of quality of urinary bladder filling in CT urography with different doses of furosemide in the work-up of patients with macroscopic hematuria. <b>2021</b> , 27, 136-141	0
206	Significant reduction of indeterminate (atypical) diagnosis after implementation of The Paris System for Reporting Urinary Cytology: A single-institution study of more than 27,000 cases. <b>2021</b> , 129, 114-120	1
205	Epidemiology of Bladder Cancer: Trends and Disparities. <b>2021</b> , 1-12	
204	The Impact of Progression on Healthcare Resource Utilization and Costs Among Patients with High-Grade Non-Muscle Invasive Bladder Cancer After Bacillus Calmette-Guérin Therapy: A Retrospective SEER-Medicare Analysis. <b>2021</b> , 38, 1584-1600	0
203	Research Progress of Urine Biomarkers in the Diagnosis, Treatment, and Prognosis of Bladder Cancer. <b>2021</b> , 1306, 61-80	
202	Introduction to Urinary Bladder Pathology. <b>2021</b> , 1-5	
201	The Controlling Nutritional Status CONUT Score in Patients With Advanced Bladder Cancer After Radical Cystectomy. <b>2021</b> , 35, 999-1006	2
200	Bladder Cancer Screening, Signs and Symptoms, and Workup. <b>2021</b> , 3-8	
199	Expression of Semaphorin 3A in Malignant and Normal Bladder Tissue: Immunohistochemistry Staining and Morphometric Evaluation. <b>2021</b> , 10,	
198	Circulating Cell-Free DNA in Liquid Biopsies as Potential Biomarker for Bladder Cancer: A Systematic Review. <b>2021</b> , 13,	2
197	Imaging of Bladder Cancer: Standard Applications and Future Trends. <b>2021</b> , 57,	5
196	Sarcomatoid Urothelial Carcinoma With Myxoid Stroma: A Case Report and Diagnostic Approach. <b>2021</b> , 13, e14007	



195	EPDR1 is related to stages and metastasize in bladder cancer and can be used as a prognostic biomarker. <b>2021</b> , 21, 71	1
194	Canadian Urological Association guideline on the management of non-muscle-invasive bladder cancer - Full-text. <b>2021</b> , 15, E424-E460	1
193	Survivin and Her2 Expressions in Different Grades of Urothelial Neoplasms of Urinary Bladder. <b>2021</b> , 16, 154-161	1
192	VNTR polymorphism in the breakpoint region of ABL1 and susceptibility to bladder cancer. <b>2021</b> , 14, 121	1
191	Adhesion GPR123 is an indicator for recurrence and prognosis in bladder cancer. <b>2021</b> , 43, 1317-1325	
190	Clinical and morphological features of non-muscle invasive bladder cancer: implications for treatment, prognosis and relapse of the disease (literature review). <b>2021</b> , 17, 134-141	1
189	The effectiveness and value of nadofaragene firadenovec, oportuzumab monatox, and pembrolizumab for BCG-unresponsive non-muscle-invasive bladder cancer. <b>2021</b> , 27, 797-804	0
188	The Inverse Association of Body Mass Index with Lung Cancer: Exploring Residual Confounding, Metabolic Aberrations and Within-Person Variability in Smoking. <b>2021</b> , 30, 1489-1497	0
187	Study Progress of Noninvasive Imaging and Radiomics for Decoding the Phenotypes and Recurrence Risk of Bladder Cancer. <b>2021</b> , 11, 704039	1
186	Incidence trends and survival prediction of urothelial cancer of the bladder: a population-based study. <b>2021</b> , 19, 221	2
185	Prognostic Implications of Immune-Related Gene Pairs Signatures in Bladder Cancer. <b>2021</b> , 2021, 5345181	0
184	Enhanced Recovery After Surgery and Radical Cystectomy: A Systematic Review and Meta-Analysis. <b>2021</b> , 13, 535-547	1
183	Fabrication, optimisation and evaluation of cisplatin-loaded nanostructured carriers for improved urothelium permeability for intravesical administration. <b>2021</b> , 38, 405-413	
182	PLD1 promotes tumor invasion by regulation of MMP-13 expression via NF- $\kappa$ B signaling in bladder cancer. <b>2021</b> , 511, 15-25	2
181	Immunotherapy of High Risk Non-Muscle Invasive Bladder Cancer. <b>2021</b> , 14, 1345-1352	1
180	Overexpression of ROCK1 promotes cancer cell proliferation and is associated with poor prognosis in human urothelial bladder cancer. <b>2021</b> , 32, 466-475	0
179	Bladder cancer: shedding light on the most promising investigational drugs in clinical trials. <b>2021</b> , 30, 837-855	4
178	MiR-186-5p suppresses cell migration, invasion, and epithelial mesenchymal transition in bladder cancer by targeting RAB27A/B. <b>2021</b> , 36, 2174-2185	3

177	Segmentation of the urothelium in optical coherence tomography images with dynamic contrast. <b>2021</b> , 26,	1	
176	Urine tumor DNA detection of minimal residual disease in muscle-invasive bladder cancer treated with curative-intent radical cystectomy: A cohort study. <b>2021</b> , 18, e1003732	5	
175	A novel survival model based on a Ferroptosis-related gene signature for predicting overall survival in bladder cancer. <b>2021</b> , 21, 943	5	
174	T1 Bladder Cancer: Comparison of the Prognostic Impact of Two Substaging Systems on Disease Recurrence and Progression and Suggestion of a Novel Nomogram. <b>2021</b> , 8, 704902	0	
173	The Utility of Nicotinamide N-Methyltransferase as a Potential Biomarker to Predict the Oncological Outcomes for Urological Cancers: An Update. <b>2021</b> , 11,	2	
172	CircRNAs and their regulatory roles in cancers. <b>2021</b> , 27, 94	11	
171	Control computerized tomography in neoadjuvant chemotherapy for muscle invasive urinary bladder cancer has no value for treatment decisions and low correlation with nodal status. <b>2021</b> , 55, 455-460	1	
170	Diagnostic accuracy of cystoscopic biopsy for tumour grade in outpatients with urothelial carcinoma of the bladder and the risk factors of upgrading. <b>2021</b> ,		
169	Saudi patient knowledge and awareness regarding smoking as a risk factor for urological diseases.. <b>2022</b> , 14, 67-72		
168	Orthodenticle homeobox OTX1 is a potential prognostic biomarker for bladder cancer. <b>2021</b> , 12, 6559-6571	5	
167	Expression profiles, biological functions and clinical significance of circRNAs in bladder cancer. <b>2021</b> , 20, 4	31	
166	Neoplasms of the urinary bladder. <b>2008</b> , 258-351	11	
165	Bladder Cancer. <b>2014</b> , 1445-1462.e4	4	
164	Effect of adjuvant chemotherapy in locally advanced urothelial carcinoma of the bladder treated with cystectomy. <b>2020</b> , 44, 94-102	1	
163	The Current Status and Future Role of the Phosphoinositide 3 Kinase/AKT Signaling Pathway in Urothelial Cancer: An Old Pathway in the New Immunotherapy Era. <i>Clinical Genitourinary Cancer</i> , <b>2018</b> , 16, e269-e276	3-3	33
162	Intravesical Bacillus Calmette-Guerin and its complications: 12 years of learning experience in a single local institution. <b>2020</b> ,		0
161	Diagnostic Utility of Serum Golgi Phosphoprotein 3 in Bladder Cancer Patients. <b>2019</b> , 25, 6736-6741		3
160	Current Status of Functional Studies on Circular RNAs in Bladder Cancer and their Potential Role as Diagnostic and Prognostic Biomarkers: A Review. <b>2019</b> , 25, 3425-3434		9

159	Identifying non-muscle-invasive and muscle-invasive bladder cancer based on blood serum surface-enhanced Raman spectroscopy. <b>2019</b> , 10, 3533-3544	23
158	Downregulation of HIPK2 increases resistance of bladder cancer cell to cisplatin by regulating Wip1. <b>2014</b> , 9, e98418	18
157	Spontaneous rupture of continent cutaneous urinary diversion after 25 years. <b>2017</b> , 6, 80-82	2
156	HMG5 promotes IL-6-induced epithelial-mesenchymal transition of bladder cancer by interacting with Hsp27. <b>2020</b> , 12, 7282-7298	5
155	Identification of an immune-related long non-coding RNA signature and nomogram as prognostic target for muscle-invasive bladder cancer. <b>2020</b> , 12, 12051-12073	13
154	Cheliensisin A (Chel A) induces apoptosis in human bladder cancer cells by promoting PHLPP2 protein degradation. <b>2016</b> , 7, 66689-66699	4
153	Narrow band imaging-assisted transurethral resection reduces the recurrence risk of non-muscle invasive bladder cancer: A systematic review and meta-analysis. <b>2017</b> , 8, 23880-23890	36
152	A potential prognostic lncRNA signature for predicting survival in patients with bladder urothelial carcinoma. <b>2017</b> , 8, 10485-10497	35
151	Antitumor activity of the c-Myc inhibitor KSI-3716 in gemcitabine-resistant bladder cancer. <b>2014</b> , 5, 326-37	27
150	FOX1 predicts overall and disease specific survival in muscle-invasive urothelial carcinoma and presents a differential expression between bladder cancer subtypes. <b>2017</b> , 8, 47595-47606	14
149	Recommended oral sodium bicarbonate administration for urine alkalinization did not affect the concentration of mitomycin-C in non-muscle invasive bladder cancer patients. <b>2017</b> , 8, 96117-96125	3
148	Increased expression of SUMO1P3 predicts poor prognosis and promotes tumor growth and metastasis in bladder cancer. <b>2016</b> , 7, 16038-48	36
147	Radical cystectomy: a review of techniques, developments and controversies. <b>2020</b> , 9, 3073-3081	5
146	Implementation of Humane Endpoints in a Urinary Bladder Carcinogenesis Study in Rats. <b>2017</b> , 31, 1073-1080	4
145	Epidemiology and unmet needs of bladder cancer in Italy: a critical review. <b>2020</b> , 72, 1-12	7
144	Section 8 Handling of surgical specimens. <b>2007</b> , 243-244	2
143	Oblongifolin C reverses GEM resistance via suppressing autophagy flux in bladder cancer cells. <b>2020</b> , 20, 1431-1440	4
142	An improved mouse orthotopic bladder cancer model exhibiting progression and treatment response characteristics of human recurrent bladder cancer. <b>2020</b> , 19, 833-839	4

141	Saudi Oncology Society clinical management guidelines for urinary bladder cancer. <b>2011</b> , 3 Suppl, S6-9	1
140	Genitourinary cancers: Summary of Indian data. <b>2016</b> , 5, 122-4	9
139	Is cystoscopy follow-up protocol safe for low-risk bladder cancer without muscle invasion?. <b>2020</b> , 12, 25-30	2
138	Saudi Oncology Society and Saudi Urology Association combined clinical management guidelines for urothelial cell carcinoma of the urinary bladder 2017. <b>2018</b> , 10, 133-137	2
137	EORTC risk tables - their usefulness in the assessment of recurrence and progression risk in non-muscle-invasive bladder cancer in Polish patients. <b>2013</b> , 66, 14-20	15
136	Canadian guidelines for treatment of non-muscle invasive bladder cancer: a focus on intravesical therapy. <b>2010</b> , 4, 168-73	35
135	Surgical management of bladder transitional cell carcinoma in a vesicular diverticulum: case report. <b>2011</b> , 5, E60-4	8
134	Neutrophil-lymphocyte ratio as a predictor of recurrence and progression in patients with high-grade pT1 bladder cancer. <b>2015</b> , 9, E126-31	21
133	CUA guidelines on the management of non-muscle invasive bladder cancer. <b>2015</b> , 9, E690-704	53
132	Mycobacterial Osteomyelitis of the Spine Following Intravesical BCG Therapy for Bladder Cancer. <b>2016</b> , 8, e545	12
131	Pelvic Genitourinary Oncology. <b>2021</b> , 37, 380-386	
130	F-Sodium Fluoride (NaF) Uptake in Calcified Bladder Carcinoma: Double Density Sign. <b>2021</b> , 30, 190-192	0
129	Restaging TURBT. <b>2009</b> , 26-33	
128	Prediction of Bladder Cancer Recurrences Using Artificial Neural Networks. <b>2010</b> , 492-499	
127	Cystectomy for Nonmuscle-Invasive Bladder Cancer. <b>2011</b> , 297-310	
126	Bladder Cancer Epidemiology. <b>2011</b> , 1-22	
125	Malignant Bladder Lesions. <b>2011</b> , 1224-1232	
124	Cancer de la vessie/uretère. <b>2011</b> , 485-494	

123 Bladder Cancer. **2011**, 511-525

122 Microwave-induced hyperthermia and microwave tissue coagulation for bladder cancer patients. **2012**, 30, 231-237

121 Tumors and Tumor-Like Conditions of Urinary Bladder, Renal Pelvis, Ureter and Urethra. **2015**, 63-194

120 ROLE OF USG AND MDCT IN EVALUATION OF URINARY BLADDER MASS. **2014**, 3, 13490-13500

119 Circulating Blood-Borne microRNAs as Biomarkers in Solid Tumors. **2015**, 106, 75-122 4

118 Onkologische Erkrankungen und postoperative Veränderungen der Harnblase und der ableitenden Harnwege. **2015**, 241-254

117 Infektionskrankheiten und Verletzungen der Harnblase und der ableitenden Harnwege. **2015**, 229-240

116 Adenocarcinoma. **2016**, 418-419

115 Saudi Oncology Society and Saudi Urology Association combined clinical management guidelines for urothelial cell carcinoma of the urinary bladder. **2016**, 8, 131-5

114 Diagnostic Applications of Nuclear Medicine: Kidney and Bladder Cancer. **2016**, 1-43

113 Comparison of CT Urography and MRI in Bladder Cancer Detection. **2016**, 28, 55-62

112 Cancer Genetics at a Glance: The Comprehensive Insights. **2017**, 79-389 1

111 Outcomes of BCG Induction in High-Risk Non-Muscle-Invasive Bladder Cancer Patients (NMIBC): A Retrospective Cohort Study. **2017**, 9, e957 1

110 Diagnostic Applications of Nuclear Medicine: Kidney and Bladder Cancer. **2017**, 839-881

109 Indications, results, and significance of early repeat transurethral resection of bladder tumours. **2017**, 18, 14-16

108 Risk Stratification and Prognostication of Bladder Cancer. **2018**, 1-14

107 Adenocarcinoma. **2018**, 242-243

106 A View of the Future: The Role of Pathologists. **2018**, 113-117

- 105 Comparison of the EORTC and CUETO prognostic models in non-muscle-invasive bladder cancer. **2018**, 14, 162-170
- 104 Comprehensive assessment of oncological outcomes in 186 patients with high-risk non-muscle-invasive bladder cancer: A single institution retrospective study. **2020**, 13, 16 1
- 103 Multi-Slice Spiral Computed Tomography Image Features under Hybrid Iterative Reconstruction Algorithm in Staging Diagnosis of Bladder Cancer. **2021**, 2021, 7733654
- 102 Ubiquitination-Related Molecular Subtypes and a Novel Prognostic Index for Bladder Cancer Patients. **2021**, 27, 1609941 1
- 101 Proteomic profiling of bladder cancer for precision medicine in the clinical setting: A review for the busy urologist. **2020**, 61, 539-554 2
- 100 Long-term follow-up of Holmium-YAG laser vaporisation of bladder urothelial carcinoma. 205141582098120
- 99 PET/CT in Renal, Bladder, and Testicular Cancer. **2020**, 731-754
- 98 Molecular subtypes of bladder cancer and first success in personalized treatment. **2020**, 16, 106-113
- 97 VI. Niere Und Harnwege. 145-160
- 96 Eosinophilia in routine blood samples as a biomarker for solid tumor development - A study based on The Copenhagen Primary Care Differential Count (CopDiff) Database. **2013**,
- 95 The clinical use of PET with (11)C-acetate. **2012**, 2, 33-47 97
- 94 Critical evaluation of vinflunine in the treatment of refractory metastatic urothelial carcinoma. **2010**, 2, 99-108 2
- 93 Increased expression of SPRY4-IT1 predicts poor prognosis and promotes tumor growth and metastasis in bladder cancer. **2015**, 8, 1954-60 48
- 92 Expression of Rab1A in bladder cancer and its clinical implications. **2020**, 20, 44
- 91 Molecular Pathways in Low and High-grade Non-muscle Invasive Bladder Cancer as Revealed by Several OMICs Data Analyses. **2021**, 1,
- 90 Expression of Spred2 in the urothelial tumorigenesis of the urinary bladder. **2021**, 16, e0254289
- 89 Soluble PD-L1 in Serum and Urine in Urinary Bladder Cancer Patients. **2021**, 13, 1
- 88 Risk of bladder cancer death in patients younger than 50 with non-muscle-invasive and muscle-invasive bladder cancer. **2021**, 1-7 1

87	One-Step Microfluidic Fabrication of Multi-Responsive Liposomes for Targeted Delivery of Doxorubicin Synergism with Photothermal Effect. <b>2021</b> , 16, 7759-7772	3
86	Correlation between aryl hydrocarbon receptor and IL-17 and Foxp3 T-cell infiltration in bladder cancer. <b>2021</b> , 102, 249-259	1
85	Efficacy of Bladder Intravesical Chemotherapy with Three Drugs for Preventing Non-Muscle-Invasive Bladder Cancer Recurrence. <b>2021</b> , 2021, 2360717	1
84	Expression of Rab1A in bladder cancer and its clinical implications. <b>2020</b> , 20, 1-1	0
83	Subcategorization of T1 Bladder Cancer on Biopsy and Transurethral Resection Specimens for Predicting Progression. <b>2021</b> ,	1
82	The impact of grading scheme on non-muscle invasive bladder cancer progression: potential utility of hybrid grading schemes.. <b>2022</b> ,	1
81	Gemcitabine-Resistant Biomarkers in Bladder Cancer are Associated with Tumor-Immune Microenvironment.. <b>2021</b> , 9, 809620	0
80	Rare tumours of the bladder: A Saudi registry based descriptive study. <b>2022</b> ,	
79	Advances in Management of Bladder Cancer-The Role of Photodynamic Therapy.. <b>2022</b> , 27,	4
78	Diagnostic Applications of Nuclear Medicine: Kidney and Bladder Cancer. <b>2022</b> , 1-49	
77	Epidemiological Profile and Therapeutics Results of Bladder Carcinoma in Women. <b>2022</b> , 12, 68-74	
76	The comparison of efficacy between the connaught and TICE strains of bacillus calmette-guerin in patients with non-muscle-invasive bladder cancer in Taiwan. <b>2022</b> ,	
75	Bladder Cancer in Young Patients: Management and Outcomes. <b>2022</b> , 13, 168-178	
74	Recent developments in cancer vaccines. <b>2022</b> , 29-75	
73	Identification of the gene expression changes and gene regulatory aspects in ELF3 mutant bladder cancer.. <b>2022</b> , 49, 3135	0
72	Predictive role of ferroptosis-related long non-coding RNAs in bladder cancer and their association with immune microenvironment and immunotherapy response.. <b>2022</b> , 20, 47	0
71	Construction and Validation of a 15-Top-prognostic-gene-based Signature to Indicate the Dichotomized Clinical Outcome and Response to Targeted Therapy for Bladder Cancer Patients.. <b>2022</b> , 10, 725024	
70	Detection rate of CIS during TURBT following shift from PDD to NBI in a single University Hospital. <i>Urology</i> , <b>2021</b> ,	1.6 2

69	LncRNA HEIH/miR-4500/IGF2BP1/c-Myc Feedback Loop Accelerates Bladder Cancer Cell Growth and Stemness. <b>2022</b> , 1-13	
68	Development and Validation of a Prognostic Nomogram for Predicting Overall Survival for T1 High-Grade Patients After Radical Cystectomy: A Study Based on SEER.. <b>2022</b> , 15, 3753-3765	
67	Metformin Use on Incidence and Oncologic Outcomes of Bladder Cancer Patients With T2DM: An Updated Meta-Analysis.. <b>2022</b> , 13, 865988	
66	Race, ethnicity, and gender reporting in North American clinical trials for BCG-unresponsive non-muscle invasive bladder cancer.. <b>2021</b> ,	0
65	Curcumin May Prevent Basement Membrane Disassembly by Matrix Metalloproteinases and Progression of the Bladder Cancer.. <b>2021</b> , 14,	0
64	Evaluation of Functional Outcomes and Quality of Life in Elderly Patients (>75 y.o.) Undergoing Minimally Invasive Radical Cystectomy with Single Stoma Ureterocutaneostomy vs. Bricker Intracorporeal Ileal Conduit Urinary Diversion.. <b>2021</b> , 11,	1
63	Metabolomic Approaches for Detection and Identification of Biomarkers and Altered Pathways in Bladder Cancer.. <b>2022</b> , 23,	5
62	Table_1.DOC. <b>2020</b> ,	
61	Classification of tissue biopsies by Raman spectroscopy guided by quantitative phase imaging and its application to bladder cancer.. <b>2022</b> , e202200009	1
60	Cost-Effectiveness of Avelumab Maintenance Therapy Plus Best Supportive Care vs. Best Supportive Care Alone for Advanced or Metastatic Urothelial Carcinoma.. <b>2022</b> , 10, 837854	
59	The Role of Adjuvant Single Postoperative Instillation of Gemcitabine for Non-Muscle-Invasive Bladder Cancer: A Systematic Review and Meta-Analysis. <b>2022</b> , 12, 1154	0
58	Diagnostic Applications of Nuclear Medicine: Kidney and Bladder Cancer. <b>2022</b> , 1-49	
57	Prognostic Value of Platelet-to-Lymphocyte Ratio in Non-Muscle Invasive Bladder Cancer Patients: Intravesical Bacillus Calmette-Guerin Treatment After Transurethral Resection of Bladder Tumor. <b>2022</b> , 9,	0
56	Emerging treatment landscape of non-muscle invasive bladder cancer. 1-18	0
55	Urinary Tract Tumor Organoids Reveal Eminent Differences in Drug Sensitivities When Compared to 2-Dimensional Culture Systems. <b>2022</b> , 23, 6305	1
54	Tumors of the Urinary Bladder. <b>2021</b> , 345-559	
53	miR-590Bp: A double-edged sword in the oncogenesis process. <b>2022</b> , 32, 100593	
52	Risk-based assessment of the impact of intravesical therapy on recurrence-free survival rate following resection of suspected low-grade, non-muscle-invasive bladder cancer (NMIBC): a Southwest Oncology Groups (SWOG) S0337 post-hoc analysis. <i>Clinical Genitourinary Cancer</i> , <b>2022</b> ,	3.3 0



51	Comprehensive Characterization of Necroptosis-Related lncRNAs in Bladder Cancer Identifies a Novel Signature for Prognosis Prediction. <i>Disease Markers</i> , <b>2022</b> , 2022, 1-30	3.2	0
50	Upregulation of Cartilage Oligomeric Matrix Protein Predicts Poor Prognosis in Urothelial Carcinoma. <i>OncoTargets and Therapy</i> , Volume 15, 727-740	4.4	
49	Invasive Cancerous Area Detection in Non-Muscle Invasive Bladder Cancer Whole Slide Images. <b>2022</b> ,		0
48	LINC00702-mediated DUSP1 transcription in the prevention of bladder cancer progression: Implications in cancer cell proliferation and tumor inflammatory microenvironment. <i>Genomics</i> , <b>2022</b> , 110428	4.3	0
47	Characterization of novel small non-coding RNAs and their modifications in bladder cancer using an updated small RNA-seq workflow. <i>Frontiers in Molecular Biosciences</i> , 9,	5.6	0
46	Clinical and biological markers for risk-stratification of T1 high-grade non-muscle invasive bladder cancer. <i>Current Opinion in Urology</i> , Publish Ahead of Print,	2.8	1
45	Pyroptosis-Related Gene to Construct Prognostic Signature and Explore Immune Microenvironment and Immunotherapy Biomarkers in Bladder Cancer. <i>Frontiers in Genetics</i> , 13,	4.5	1
44	Prognostic values of the immune microenvironment-related non-coding RNA IGF2BP2-AS1 in bladder cancer. <i>Cell Cycle</i> , 1-17	4.7	
43	Large-scale human tissue analysis identifies Uroplakin 1a as a putative diagnostic marker for urothelial cancer. <i>Pathology Research and Practice</i> , <b>2022</b> , 237, 154028	3.4	
42	5-Aminolevulinic Acid-Based Photodynamic Diagnosis for Detection of Urothelial Carcinoma Cells in Bladder Washing Sediment Suspension: A Pilot Study. <b>2022</b> , 103072		
41	Identification of MAN1B1 as a Novel Marker for Bladder Cancer and Its Relationship with Immune Cell Infiltration. <b>2022</b> , 2022, 1-10		
40	Preoperative Free Ferrous Protoporphyrin and Reactive Oxygen Species Status of Voided Urine Predicts Potential Recurrence Risk in NMIBC. Volume 14, 2291-2297		0
39	Construction and validation of a gene signature related to bladder urothelial carcinoma based on immune gene analysis. <b>2022</b> , 22,		
38	N-(3,4-dimethoxyphenethyl)-6-methyl-2,3,4,9-tetrahydro-1 H -carbazol-1-amine inhibits bladder cancer progression by suppressing YAP1 / TAZ.		0
37	Prioritizing potential circRNA biomarkers for bladder cancer and bladder urothelial cancer based on an ensemble model. 13,		0
36	Curcumin in the treatment of urological cancers: Therapeutic targets, challenges and prospects. <b>2022</b> , 309, 120984		4
35	PENet: Prior evidence deep neural network for bladder cancer staging. <b>2022</b> , 207, 20-28		0
34	Delayed diagnosis of bladder cancer in a patient with autosomal dominant polycystic kidney disease. <b>2022</b> , 0		0

- 33 Diagnostic Applications of Nuclear Medicine: Kidney and Bladder Cancer. **2022**, 975-1022 ○
- 32 The research status of adjuvant therapy for non-muscular invasive bladder cancer. **2022**, ○
- 31 Establishment of an optimized orthotopic bladder cancer model in mice. **2022**, 22, ○
- 30 Glabridin inhibits urothelial bladder carcinoma cell growth in vitro and in vivo by inducing cell apoptosis and cell cycle arrest. ○
- 29 Expression of GLUT4 and FAP in urothelial bladder carcinoma: correlation with angiogenesis and clinicopathological characteristics. **2022**, 34, ○
- 28 Role of the JNK Pathway in Bladder Cancer. Volume 15, 963-971 ○
- 27 Modified immunoscore improves the prediction of progression-free survival in patients with non-muscle-invasive bladder cancer: A digital pathology study. 12, 1
- 26 Urinary exosomal long non-coding RNAs as noninvasive biomarkers for diagnosis of bladder cancer by RNA sequencing. 12, ○
- 25 Incidental diagnosis of bladder cancer in a national observational study in Spain. **2022**, ○
- 24 Survival Outcome of Partial Cystectomy versus Transurethral Bladder Tumor Resection in T1 High-Grade Bladder Cancer Patients: A Propensity Score Matching Study. **2022**, 2022, 1-17 ○
- 23 Diagnóstico incidental del cáncer de vejiga en España. Estudio observacional a nivel nacional. **2022**, ○
- 22 Influence of Antibiotic Administration on the Urinary Bladder Cancer Early Recurrence Rate. **2022**, 2022, 1-10 ○
- 21 Exploitation of tumor antigens and construction of immune subtype classifier for mRNA vaccine development in bladder cancer. 13, ○
- 20 Did the Scientific Innovations in the Management of Non-Muscle Invasive Bladder Cancer Patients Improve the Outcome during the Last 2 Decades?. **2022**, 12, 563-587 ○
- 19 The comparison between contrast-enhanced ultrasound and contrast-enhanced magnetic resonance imaging in diagnosing bladder urothelial carcinoma. ○
- 18 Does Bladder Cancer with Inchworm Sign Indicate Better Prognosis after TURBT?. **2022**, 14, 5767 ○
- 17 Cost-Effectiveness of Nadofaragene Firadenovec and Pembrolizumab in Bacillus Calmette-Guérin (BCG)-Unresponsive Non-Muscle Invasive Bladder Cancer. **2022**, ○
- 16 Mutational Landscape of Bladder Cancer in Mexican Patients: KMT2D Mutations and chr11q15.5 Amplifications Are Associated with Muscle Invasion. **2023**, 24, 1092 ○

- 15 An angiogenesis-related lncRNA signature for the prognostic prediction of patients with bladder cancer and LINC02321 promotes bladder cancer progression via the VEGFA signaling pathway. **2022**, 27, ○
- 14 Identification and validation of tumor-infiltrating lymphocyte-related prognosis signature for predicting prognosis and immunotherapeutic response in bladder cancer. **2023**, 24, ○
- 13 A New Global Voice for People Affected by Bladder Cancer. 42-43 ○
- 12 miRNAs role in bladder cancer pathogenesis and targeted therapy: Signaling pathways interplay A review. **2023**, 242, 154316 ○
- 11 Immunotherapy in the Treatment of Metastatic Urothelial Carcinoma at a Tertiary Referral Center in Portugal. **2023**, 36, 145-146 ○
- 10 Bladder Perforation during Transurethral Resection of Bladder Tumor Is Not an Innocent Accident: Literature Review Based on a Clinical Case Experience. **2023**, 13, 49-54 ○
- 9 TULA DUAL: Trans Urethral Laser Ablation of recurrent bladder tumors in outpatient setting. ○
- 8 Performing Automatic Identification and Staging of Urothelial Carcinoma in Bladder Cancer Patients Using a Hybrid Deep-Machine Learning Approach. **2023**, 15, 1673 ○
- 7 Bladder Cancer and Risk Factors: Data from a Multi-Institutional Long-Term Analysis on Cardiovascular Disease and Cancer Incidence. **2023**, 13, 512 ○
- 6 Prognostic value of tumor budding in urothelial carcinoma: A meta-analysis and systematic review. **2023**, 100136 ○
- 5 Circulating and urinary tumour DNA in urothelial carcinoma Upper tract, lower tract and metastatic disease. ○
- 4 Natural Products as New Approaches for Treating Bladder Cancer: From Traditional Medicine to Novel Drug Discovery. **2023**, 15, 1117 ○
- 3 Potential mechanisms of osthole against bladder cancer cells based on network pharmacology, molecular docking, and experimental validation. **2023**, 23, ○
- 2 Prognostic value of immunogenic cell death genes in bladder cancer. ○
- 1 Detection of the ADGRG6 hotspot mutations in urine for bladder cancer early screening by ARMS-qPCR. ○